

INNOVATION

2009 ANNUAL REPORT



**The Leukemia &
Lymphoma Society®**
Fighting Blood Cancers

CURE LEUKEMIA, LYMPHOMA,
HODGKIN'S DISEASE AND
MYELOMA, AND IMPROVE
THE QUALITY OF LIFE OF
PATIENTS AND THEIR FAMILIES.

MISSION

PRESIDENT & CHAIRMAN'S MESSAGE

In looking back on The Leukemia & Lymphoma Society's (LLS) 60 years, there is one defining characteristic that shows up in everything we do: Innovation. It is evident in every area of our mission, from our research track record, through innovative patient services programs and in new legislative victories that address the needs of the blood cancer population. This year's report will highlight some of the innovations that have helped patients with blood cancers live better, longer lives and show some of the survivors who have benefited from LLS innovations.

More than anything else, this 60th anniversary is a time when we are looking forward. The landscape in which we live and work is going through powerful changes and we grasp the need to adapt quickly, moving toward a culture that supports and nurtures fresh perspectives and solutions at every level of our organization, from the local chapter to the national board room.

We have created a legacy of innovation. Now, it's time to re-commit, with new vigor and resolve, as we remember the words of the German poet and intellectual, Goethe: *"Whatever you can do or dream you can, begin it. Boldness has a genius, power and magic in it."*



John E. Walter ■ President and CEO



Steven L. Hooker ■ Chair



60 YEARS OF INNOVATION

LLS is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. Over our 60 years of existence, we have thrived on a spirit of innovation in all aspects of our mission. Our continuous support for the best research, wherever in the world it is being done, is a testament to innovation.

VIATION



INNOVATIONS IN RESEARCH

When LLS was founded in 1949, a diagnosis of leukemia, lymphoma or myeloma was almost always fatal. Today, thanks to innovative research funded in part by LLS, survival rates for some blood cancers have doubled, or even tripled. In fact, some blood cancer survival rates rose as much as four-fold from 1960 to 2005.

LLS-funded research programs include traditional grants to individual researchers and research teams as well as the more recent model of funding projects at companies and health organizations that will accelerate the advancement of our mission. These programs support discoveries that have led or contributed to new treatments and that have saved the lives of patients battling many types of cancer. Read about two such innovations below.

❖ GLEEVEC®

Ten years ago, the five-year survival rate for patients with chronic myelogenous leukemia (CML) was less than 50 percent. Then, an LLS-funded researcher, Brian Druker, MD, developed the targeted drug Gleevec® (approved 2001). Now, the survival rate for patients with newly diagnosed, chronic phase CML has nearly doubled, to 95 percent, and they enjoy a high quality of life. Gleevec is also FDA-approved for patients with a rare form of stomach cancer called GIST, and the drug is being tested for patients with many other kinds of malignancies.

❖ THERAPY ACCELERATION PROGRAM

Innovations in research have helped us become the third-largest generator of private support among all U.S. voluntary health organizations – behind only The American Cancer Society and The American Heart Association. This is truly phenomenal when you consider the “orphan status” of our diseases.

One such innovation that makes the future look even brighter for patients with blood cancers is a new program that will bring more treatments to more patients faster. Through our *Therapy Acceleration Program*, we are partnering with biotechnology companies to facilitate the rapid development of promising new therapies that might otherwise go undeveloped. The program is also helping to overcome a key barrier in getting patients into clinical trials by developing novel models that will bring those trials into communities where patients live. And the *Therapy Acceleration Program* is accelerating the development of new discoveries in its pipeline by funding applied research, paving the way for FDA approval.

“Our LLS chapter has been there for us, with support and information that has helped immensely. We’ve formed a Friends and Family Team for Light The Night Walk and it feels so rewarding to raise funds to help others who, like Layla, are bravely battling blood cancers.”

❖ ALECIA HEFTER
LAYLA’S MOM

INNOVATIONS IN PATIENT SERVICES

Nearly 913,000 people across the United States currently battle leukemia, lymphoma and myeloma. LLS offers a comprehensive array of services to guide blood cancer patients and their caregivers to make informed decisions, access the most current treatment and clinical trial options and provide support services so each patient may have the best possible outcome and quality of life. Last year alone, LLS made 4.9 million contacts with patients, caregivers and healthcare professionals.

❖ INFORMATION RESOURCE CENTER

Only LLS provides individualized information to patients and their caregivers about blood cancers, resources, treatments and other critical issues through our Information Resource Center.

❖ PEDIATRIC CANCERS

We have created and implemented an innovative program, *The Trish Greene Back to School Program for Children with Cancer*, to help smooth the way for children returning to school after cancer treatment, with education and tools for teachers and school personnel.

❖ FIRST CONNECTION

This novel peer-to-peer program, started in 1995, matches newly diagnosed patients and family members with trained volunteers who have been through similar cancer journeys, and arranges contact. The program is provided through LLS chapters in communities throughout the U.S. and Canada.

LAYLA HEFTER

IN THIS PHOTO, LAYLA WAS THREE AND HAD SUCCESSFULLY COMPLETED HER FIRST YEAR OF CHEMO TO TREAT ACUTE LYMPHOCYTIC LEUKEMIA (ALL). IN SPITE OF ALL SHE'S GONE THROUGH, SHE'S STILL SMILING! SHE ENJOYS READING BOOKS WITH HER MOM, PLAYING WITH HER PRINCESS DOLLS AND ESPECIALLY, VISITING THE ANIMALS AT THE ZOO. THESE DAYS, LAYLA IS LOOKING FORWARD TO HER 2½ YEARS OF TREATMENT TO BE OVER AND, THANKS TO RESEARCH, SHE SHOULD HAVE A FUTURE WITH PLENTY OF TIME FOR SMILES.



“*Since being diagnosed with myeloma, I’ve been glad to have the assistance of LLS. For one thing, research they helped fund resulted in Velcade[®], one of the drugs I’m being treated with. For another, their financial assistance program has come in very handy during my illness. Thank goodness for LLS.”*

✦ MANUEL TAPIA


INNOVATIONS IN ADVOCACY

LLS has made vital contributions that advance our mission through advocacy at both state and national government levels. In past years, for example, we helped initiate the first blood cancer lobby day in Washington, D.C.; we have advocated for legislation to continue insurance coverage for standard-care costs when patients participate in clinical trials, with coverage now expanded to 28 states; championed the first legislation in the country to provide neuro-psychological testing for pediatric cancer survivors; helped establish the first blood cancer research program at the Department of Defense; and initiated a blood cancer patient education program funded through the Centers for Disease Control and Prevention.

INNOVATIONS IN FUNDRAISING

Our signature fundraising program, Team In Training[®] (TNT), is the world’s first and largest charity sports training program, raising nearly \$1 billion for blood cancer research and patient support since its inception 21 years ago! Often imitated, but never equaled, TNT makes a major impact on the lives of people battling blood cancers.

LLS entered online search and fundraising early. These efforts have not only proven to be successful, but also have caught the attention of Google, which has been generous with its support and is currently writing a case history based on our experience.



MANUEL TAPIA

YOU CAN TELL JUST BY LOOKING AT HIM THAT MANUEL HAS A POSITIVE OUTLOOK. IT HAS SERVED HIM WELL SINCE HIS DIAGNOSIS WITH MULTIPLE MYELOMA. MANUEL DRIVES A BUS IN DOWNTOWN KANSAS CITY AND WHEN ASKED WHAT HE MOST LIKES TO DO, HIS RESPONSE WAS SIMPLE: "WORKING AND WORKING OUT." AFTER CHEMOTHERAPY AND A STEM CELL TRANSPLANT, MANUEL IS IN REMISSION AND HIS HOPES FOR THE FUTURE ARE EQUALLY SIMPLE. HE WANTS TO "STAY WELL." AND THAT'S EXACTLY WHAT WE WISH FOR HIM.

LLS also has a virtual, remote, in-house center for telemarketing and customer support, improving customer service and creating cost savings.

LLS also found that strategic partnerships can have a meaningful impact on our revenue goals. Thanks to Scott Key, Team In Training Alumni and Senior Vice President of Marketing at Gap, Inc., LLS was included in Gap's Give & Get program for the first time in the spring of 2009. The discount coupon promotion helped raise \$600,000 for LLS due in large part to heavy viral promotion conducted online.

LOOKING AHEAD

Our goal is a future in which LLS has transformed the lives of people with blood cancer and the healthcare landscape that patients, families and caregivers navigate. LLS will continue to lead with innovation, embracing change to keep ahead of a world that's changing fast.

As a cancer survivor recently acknowledged, "LLS was like finding a window to hope and knowledge." This is a window that we promise will never be closed.

FISCAL YEAR 2009 HIGHLIGHTS

In 2009, LLS continued to make progress toward cures. The following pages provide updates on our mission areas and on the many programs that support them.

RESEARCH HIGHLIGHTS

LLS developed and utilizes an innovative system to support new therapies from discovery through testing and into clinical use to help blood cancer patients. Our research grant programs facilitate basic, translational and multi-disciplinary research; our *Therapy Acceleration Program* focuses on parts of the therapy development pipeline in which bottlenecks too often occur. We recently saw a wonderful example of the full strategy at work in the case of a new drug with great promise for the treatment of some patients with leukemia, lymphoma and even solid tumors.

In 2004, an LLS grant funded studies of Aaron Schimmer, MD, PhD, FRCPC, at the Ontario Cancer Institute. Dr. Schimmer's investigation focused on a protein called XIAP that had been associated with resistance to chemotherapy among patients with acute myeloid leukemia (AML). He identified chemicals that inhibit this protein and confirmed that these targeted drugs could help kill AML cells.

In 2007, Dr. Schimmer used additional LLS funding to extend his earlier work into clinical studies of a particularly promising anti-XIAP drug (AEG35156). It was used in combination with chemotherapy in 51 AML patients and found safe and effective, producing remissions in nearly half of the patients for whom other therapies had failed.

LLS continues to help advance this promising new therapy through its *Therapy Acceleration Program*, supporting new trials of AEG35156. This time, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and two types of lymphomas are being enrolled in a Phase I study to determine the safety and optimal dose of this drug. A Phase II study will follow to measure the drug's effectiveness at the highest safe dose.

The *Therapy Acceleration Program* also takes clinical trials to patients where they live. CLL and lymphoma patients now have access to AEG35156 trials at three community treatment centers, made possible by LLS's groundbreaking partnership with the Cleveland Clinic Taussig Cancer Institute.

This story, which follows the development of a drug from basic to translational research and into clinical trials, past several points where its development might have stalled, demonstrates the importance of LLS's continuum of support, and is an LLS innovation success story.



AARON SCHIMMER
MD, PHD, FRCPC
ONTARIO CANCER
INSTITUTE

FISCAL YEAR 2009 HIGHLIGHTS

PATIENT SERVICES

- LLS's Information Resource Center (IRC), staffed by masters-level professionals responded to nearly 80,000 inquires this year helping patients navigate treatment, clinical trial options and support services.
- Over 3,200 clinical trial searches were conducted using the new IRC clinical trial search tool, Trial Check, created in partnership with the Coalition of Cancer Cooperative Groups.
- The LLS co-pay assistance program awarded over \$19.2 million in support to patients to assist them with prescription drug co-pay and insurance premium obligations.
- Over 407,000 patients, caregivers and healthcare professionals attended national LLS Web cast and teleconference blood cancer education programs and over 56,000 attended community-based LLS chapter education programs.
- LLS chapters offered 516 family support groups across the U.S. and Canada, 7,000 First Connection matches occurred matching newly diagnosed patients with trained volunteers, and nearly 3,000 school personnel, healthcare professionals and parents attended the LLS education program *"Welcome Back: Facilitating the School Experience for Childhood Cancer Survivors."*


LAURA WHITAKER

LAURA WAS DIAGNOSED WITH CLL IN 2000, AND SAYS SHE WAS, "A LITTLE LOST" UNTIL AN LLS PATIENT SERVICES MANAGER GAVE HER INFORMATION ON HER DISEASE AND TREATMENT OPTIONS, AND TOLD HER ABOUT CLINICAL TRIALS THAT HELPED GET HER CANCER INTO REMISSION. A SCHOOL LIBRARIAN, SHE ALSO GIVES BACK AS A VERY ACTIVE VOLUNTEER, PARTICIPANT AND FUNDRAISER FOR LLS. LAURA SAYS SHE LIVES WITH "ZEST AND GUSTO," AND SURROUNDS HERSELF WITH POSITIVE PEOPLE.



CONNOR OHLSON

CONNOR IS UNUSUALLY PHOTOGENIC. IT'S ALSO UNUSUAL, AND UNFORTUNATE, THAT HE WAS DIAGNOSED WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) AT AGE FOUR. CONNOR'S IN HEMATOLOGICAL REMISSION NOW AND TAKES GLEEVEC®, AN ORAL TREATMENT DEVELOPED WITH SUPPORT FROM LLS. THIS DRUG HELPS GIVE HIM A HIGH QUALITY OF LIFE SO HE CAN PLAY WITH HIS FRIENDS LIKE ANY OTHER LITTLE BOY. LAST YEAR, HIS FAMILY FORMED "TEAM CONNOR" AND RAISED MONEY THROUGH LIGHT THE NIGHT WALK – TO HELP LLS FIND BETTER TREATMENTS, AND EVENTUALLY, CURES FOR KIDS LIKE CONNOR.



ADVOCACY

- LLS volunteer advocates led coalition efforts that garnered passage of legislation in Colorado, Indiana, Oregon and Texas that ensures access and insurance coverage for patients in potentially life-saving clinical trials. This coverage is now required by 28 states and the District of Columbia.
- LLS spearheaded a patient coalition that resulted in enhanced blood cancer research at the Department of Defense in a newly focused \$20 million peer-reviewed cancer program and a new bone marrow failure disease program.
- Teamed with other pediatric cancer groups, LLS secured passage of the Carolyn Pryce Walker Conquer Childhood Cancer Act (H.R. 1553), ensuring the expansion of pediatric cancer research, increased public awareness of treatments and the creation of a national childhood cancer registry.
- LLS launched a new and improved LLS Advocates Network communication and mobilization system which provided 45,000 blood cancer advocates with fresher, more timely and targeted information, and more opportunities to get involved and make their voices heard.

FISCAL YEAR 2009 HIGHLIGHTS



FUNDRAISING

TEAM IN TRAINING

Last year, LLS launched its second, co-branded Team In Training event, the Nation's Triathlon To Benefit The Leukemia & Lymphoma Society. In its inaugural season, TNT brought 700 participants to this sold-out event, raising \$3 million to help find cures for blood cancers. In 2009, a third co-branded event, the *Womens' Running Magazine* Women's Half Marathon To Benefit The Leukemia & Lymphoma Society was created, adding to LLS's fast-growing co-branded events arena. This new half marathon will take place in November 2009, in scenic St. Petersburg, FL.

LIGHT THE NIGHT WALK

This year, new emphasis was placed on developing strategies to recruit more businesses to form teams and provide sponsorship. These include identifying, recruiting and engaging volunteers who are active in their community and well connected to serve as the Corporate Walk Chair or on Executive Committees. These volunteers will bring their contacts to Corporate Recruitment Events, helping secure new corporate teams and sponsorship. Light The Night will also continually replenish volunteers by having existing leaders replace themselves when their term is up.

SCHOOL & YOUTH PROGRAMS

These innovative programs continue to engage students in communities across the country, resulting in participation in nearly a quarter of the nation's schools. A new tactic this year, acknowledging individual classrooms with pennants to recognize their fundraising success, encouraged students to keep on fundraising. The coveted pennants – bronze, silver and gold – were awarded to classrooms who met different fundraising milestones.

MAN & WOMAN OF THE YEAR

This successful fundraising program continues its expansion into new geographies, attracting dynamic community leaders who commit themselves to raise funds to support lifesaving cancer research. The local Man & Woman of the Year titles are announced at festive gala celebrations and the top fundraisers nationwide earn the national titles. Local and national winners are congratulated in a full-page ad in *USA Today*.

DONOR DEVELOPMENT

Thanks to commitments from generous individuals, foundations, and organizations who recognize the importance of affirming the LLS mission, \$23.4 million was contributed in FY 2009 for specific initiatives. Significant income from magnanimous individuals who remembered LLS in their estate plans was also realized during this period. These deferred gifts are increasingly important as LLS seeks to heighten its impact on blood cancer research and therapy acceleration.

Funds are supporting basic and translational studies, encouraging greater access to clinical trials, and fostering partnerships among academic institutions, medical centers, and companies to accelerate new therapies to market. Outreach to patients and their families has also been enhanced, enabling LLS to provide supportive and educational resources from the earliest days of diagnosis through their journey.

Recognizing the importance of keeping generous benefactors informed, the *Giving Circle*, new this year, provides special access to experts in blood cancer research and treatment.

2009 NATIONAL MAN OF THE YEAR

DAWSON GRIMSLEY
PRESIDENT & OWNER
DAVIS-MOORE AUTO GROUP
WICHITA, KS

REESE NAYLOR
GIRL OF THE YEAR



2009 NATIONAL WOMAN OF THE YEAR

ARI JONES
MOMS FOR A CURE
FAIRFAX, VA

ALESSANDRO VALERI
BOY OF THE YEAR



RESEARCH GRANTS

SPECIALIZED CENTER OF RESEARCH

THE SPECIALIZED CENTER OF RESEARCH PROGRAM FUNDS MULTIDISCIPLINARY RESEARCH BY TEAMS OF LEADING-EDGE ACADEMIC INVESTIGATORS THAT HASTENS THE DISCOVERY AND DEVELOPMENT OF BETTER TREATMENTS FOR LEUKEMIA, LYMPHOMA AND MYELOMA PATIENTS. A CENTER IS COMPOSED OF AT LEAST THREE INDEPENDENT RESEARCH PROGRAMS THAT ARE INTEGRATED AND SUPPORTED BY SCIENTIFIC CORE LABORATORIES.

Jerry Adams, PhD*

Walter & Eliza Hall Institute of Medical Research

Frederick Alt, PhD

Immune Disease Institute

Jon Aster, MD, PhD

Brigham & Women's Hospital

Irwin Bernstein, MD*

Fred Hutchinson Cancer Research Center

John H. Bushweller, PhD¹

The Rector and Visitors of the University of Virginia

John Byrd, MD²

Ohio State University

Riccardo Dalla-Favera, MD³

Columbia University

Brian Druker, MD⁴

Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute

Carolyn Felix, MD

Children's Hospital of Philadelphia

Anthony Green, MD, PhD

University of Cambridge

James Griffin, MD⁵

Dana-Farber Cancer Institute

Helen Heslop, MD*

Baylor College of Medicine

Carl June, MD*

University of Pennsylvania

Thomas Kipps, MD, PhD

University of California, San Diego

Larry Kwak, MD, PhD

University of Texas M.D. Anderson Cancer Center

Ronald Levy, MD⁶

Stanford University

Jonathan Licht, MD

Northwestern University School of Medicine

Scott Lowe, PhD⁷

Cold Spring Harbor Laboratory

Tak Mak, PhD, DSC

University Health Network

Beverly Mitchell, MD⁸

Stanford University

Stephen Nimer, MD*

Memorial Sloan-Kettering Cancer Center

Michael Thirman, MD⁹

The University of Chicago

Cheryl Willman, MD

University of New Mexico

CAREER DEVELOPMENT PROGRAM

THE CAREER DEVELOPMENT PROGRAM PROVIDES STIPENDS TO INVESTIGATORS OF EXCEPTIONAL PROMISE IN THE EARLY STAGES OF THEIR CAREERS, HELPING THEM DEVOTE THEIR CAREERS TO LEUKEMIA, LYMPHOMA AND/OR MYELOMA RESEARCH.

Ioannis Aifantis, PhD

New York University School of Medicine

David Allman, PhD

University of Pennsylvania

Shannon Anderson, PhD

University of California, San Francisco

Philippe Armand, MD, PhD

Dana-Farber Cancer Institute

Scott Armstrong, MD, PhD^{*}

Children's Hospital Boston

Laura Attardi, PhD

Stanford University

Claire Attwooll, PhD¹⁰

Memorial Sloan-Kettering Cancer Center

Christopher Bakal, PhD

Harvard Medical School

Michael Bassik, PhD

University of California, San Francisco

Uttiya Basu, PhD

Immune Disease Institute

Linda Baughn, PhD

Albert Einstein College of Medicine

Michael Begley, PhD

Beth Israel Deaconess Medical Center

Micah Benson, PhD^{*}

Harvard Medical School

Avinash Bhandoola, MD, PhD

University of Pennsylvania

Anja-Katrin Bielinsky, PhD

University of Minnesota, Twin Cities

Susan Biggins, PhD

Fred Hutchinson Cancer Research Center

Daniel Billadeau, PhD

Mayo Clinic and Foundation

Debabrata Biswas, PhD^{*}

Rockefeller University

Dale Bixby, MD, PhD^{*}

University of Michigan

Marie Bleakley, MD

Fred Hutchinson Cancer Research Center

Marzenna Blonska, PhD

University of Texas M.D. Anderson Cancer Center

Michael Boddy, PhD^{*}

The Scripps Research Institute

Catherine Bollard, MD

Baylor College of Medicine

Niccolo Bolli, MD^{*}

Dana-Farber Cancer Institute

Tatiana Bondar, PhD¹¹

Yale University

Ivan Borrello, MD

Johns Hopkins University School of Medicine

Marina Bousquet, PhD^{*}

Whitehead Institute for Biomedical Research

Lihua Budde, MD, PhD^{*}

Fred Hutchinson Cancer Research Center

Gerd Bungartz, PhD

Massachusetts General Hospital

Laura Buttitta, PhD

Fred Hutchinson Cancer Research Center

Kenneth Campellone, PhD

University of California, Berkeley

Julie Canman, PhD

Ludwig Institute for Cancer Research

Kate Carroll, PhD

University of Michigan

Andrew Carter, PhD

University of California, San Francisco

Pedro Carvalho, PhD

Harvard Medical School

Lucio Castilla, PhD¹²

University of Massachusetts Medical School

Asher Chanan-Khan, MD

Health Research Incorporated, Roswell Park Cancer Institute Division

Yang Chao, PhD

Princeton University

Wei-Yi Chen, PhD

Rockefeller University

Xi Chen, PhD^{*}

Harvard University School of Public Health

Yi-Bin Chen, MD

Massachusetts General Hospital

Tao Cheng, MD

University of Pittsburgh

Vivian Choi, PhD

Immune Disease Institute

Yoonsu Choi, PhD^{*}

University of Texas M.D. Anderson Cancer Center

Stella Chou, MD

Children's Hospital of Philadelphia

Eric Chow, MD

Fred Hutchinson Cancer Research Center

Wen-Ming Chu, MD, PhD

Brown University

Sergei Chuikov, PhD

University of Michigan

Elaine Chung, PhD

University of Pennsylvania

Karlene Cimprich, PhD

Stanford University

Maria Ciofani, PhD

New York University School of Medicine

Pasquale Cirone, PhD

Yale University

¹ Dr. John H. Bushweller is funded in part by The Breeden-Adams Foundation.

² Dr. John Byrd is funded in part by Elaine Smith, Douglas A. and Phyllis Smith and Michael and Jacqueline Thomas.

³ Dr. Riccardo Dalla-Favera is funded in part by the Joseph S. and Diane H. Steinberg Charitable Trust.

⁴ Dr. Brian Druker is funded in part by Imagine a Cure for Leukemia.

⁵ Dr. James Griffin is funded in part by Barbour Griffith & Rogers, Carnival Cruise Lines, Eli Lilly and Company, Virginia Sheldon Jerome Foundation, Karym Research Fund, F.M. Kirby Foundation, The McManus Group LLC, National Pharmaceutical Council and Susan and Rick Theeder – Cure Kids Cancer Golf.

⁶ Dr. Ronald Levy is funded in part by John Andrews, Chris Lantman, Guy and Linda Nohra, The East Bay Community Foundation, The Wayne & Gladys Valley Foundation, The Reddere Foundation, an advised fund of the Silicon Valley Community Foundation, and two anonymous donors.

⁷ Dr. Scott Lowe is funded in part by The Altschul Foundation/Reichman Memorial.

⁸ Dr. Beverly Mitchell is funded in part by The Joseph C. Sanfilippo Memorial Fund.

⁹ Dr. Michael Thirman is funded in part by The Pamela B. Katten Memorial Leukemia Research Foundation, The Bohnen Family Foundation, Alverin M. Cornell Foundation, Paul and Joan Rubschlager Foundation, Helen Brach Foundation, William Sefton, Driehaus Capital Management, Dan Lindberg, The Arthur Foundation, The Gill Charitable Foundation, The Coleman Foundation and one anonymous donor.

Kenneth Cooke, MD¹³
Case Western Reserve University

Alexandre Costa, PhD
Stanford University

John Crispino, PhD
Northwestern University
School of Medicine

Vincenzo D'Angiolella, MD, PhD
New York University School of Medicine

Louise D'Cruz, PhD
University of California at San Diego

Monique Dail, PhD
University of California, San Francisco

Mari Dallas, MD
St. Jude Children's Research Hospital

Blossom Damania, PhD
University of North Carolina at Chapel Hill

Abhishek Datta, PhD
Immune Disease Institute

Jeffrey Davies, MD, PhD
Dana-Farber Cancer Institute

Michael Davis, PhD
Fred Hutchinson Cancer Research Center

Renee de Pooter, PhD
University of Oxford

Michael Deininger, MD, PhD
Oregon Health & Science University

Ludovic Deriano, PhD
New York University School of Medicine

Abby Dernburg, PhD
University of California, Berkeley

Luisa Di Stefano, PhD
Massachusetts General Hospital

J. Alan Diehl, PhD
University of Pennsylvania

Chen Dong, PhD
University of Texas
M.D. Anderson Cancer Center

Gregory Driessens, PhD
The University of Chicago

Jinyan Du, PhD
Harvard Medical School

Mary Eapen, MBBS*
Medical College of Wisconsin

Takeshi Egawa, MD, PhD
New York University School of Medicine

Christine Eischen, PhD
Vanderbilt University

Sheryl Elkin, PhD
Massachusetts Institute of Technology

Nicholas Endres, PhD
University of California, Berkeley

Kolja Eppert, PhD¹⁴
University Health Network

Alice Fan, MD
Stanford University

Michael Farrar, PhD
University of Minnesota, Twin Cities

Niklas Feldhahn, PhD
Rockefeller University

David Feldser, PhD
Massachusetts Institute of Technology

Pinghui Feng, PhD
University of Texas
M.D. Anderson Cancer Center

David Ferguson, MD, PhD*
University of Michigan

Adolfo Ferrando, MD, PhD¹⁵
Columbia University

Daniel Foltz, PhD
University of Virginia

Noelle Frey, MD
University of Pennsylvania

Jonathan Friedberg, MD¹⁶
University of Rochester

Kyriaki Galani, PhD
Massachusetts Institute of Technology

Boyi Gan, PhD
Dana-Farber Cancer Institute

Neil Ganem, PhD
Dana-Farber Cancer Institute

Jason Garrison, PhD
Burnham Institute for Medical Research

Benjamin Gewurz, MD, PhD
Brigham & Women's Hospital

Sourav Ghosh, PhD
University of Arizona

Florent Ginhoux, PhD
Singapore Immunology Network

Ajay Gopal, MD*
University of Washington

Wendy Gordon, PhD
Brigham & Women's Hospital

Monica Gostissa, PhD
Immune Disease Institute

Daniel Graham, PhD*
Washington University in St. Louis

H. Leighton Grimes, PhD
Cincinnati Children's Hospital
Medical Center

Alla Grishok, PhD
Columbia University

Beichu Guo, PhD
University of California, Los Angeles

Allan Gurtan, PhD
Massachusetts Institute of Technology

Sara Hamilton, PhD*
University of Minnesota, Twin Cities

Danna Hargett, PhD
Princeton University

Jin He, MD, PhD
University of North Carolina at Chapel Hill

Xi He, PhD
Children's Hospital Boston

Ian Henderson, PhD
University of California, Los Angeles

Kiersten Henderson, PhD
Fred Hutchinson Cancer Research Center

David Hesslein, PhD
University of California, San Francisco

Elizabeth Hexner, MD
University of Pennsylvania

Gilles Hickson, PhD
University of Montreal

Angela Hilliker, PhD
University of Arizona

Amy Holdorf, PhD
Mount Sinai School of Medicine

Heedeok Hong, PhD
University of California, Los Angeles

Jian Hu, PhD
Dana-Farber Cancer Institute

Jian Huang, MD, PhD
University of Pennsylvania

Jing Huang, PhD
Wistar Institute

Kristen Hurov-Neely, PhD
Brigham & Women's Hospital

Madhulika Jain, PhD
Harvard Medical School

Robert Jenq, MD
Memorial Sloan-Kettering Cancer Center

Peng Ji, MD, PhD
Whitehead Institute
for Biomedical Research

Hao Jiang, PhD
Rockefeller University

Emma Josefsson, PhD
Walter & Eliza Hall Institute
of Medical Research

Przemyslaw Juszczynski, MD, PhD
Dana-Farber Cancer Institute

Axel Kallies, PhD
Walter & Eliza Hall Institute
of Medical Research

Sumin Kang, PhD
Emory University

Tarun Kapoor, PhD¹⁷
Rockefeller University

David Kashatus, PhD
Duke University Medical Center

Samuel Katz, MD, PhD
Dana-Farber Cancer Institute

Barbara Kee, PhD
The University of Chicago

Younghoon Kee, PhD
Dana-Farber Cancer Institute

Scott Keeney, PhD
Memorial Sloan-Kettering Cancer Center

Karen Keeshan, PhD¹⁸
University College Cork

Kitai Kim, PhD
Children's Hospital Boston

TaeSoo Kim, PhD
Harvard Medical School

Scott Kogan, MD
University of California, San Francisco

Minoree Kohwi, PhD
University of Oregon

¹⁰ Dr. Claire Atwood is fully funded by the Hildegarde D. Becher Foundation.

¹¹ Dr. Tatiana Bondar is fully funded by the Gertrude B. Elion Research Fund.

¹² Dr. Lucio Castilla is funded in part by The Robert H. Lyon Leukemia Foundation and The Remillard Family Foundation.

¹³ Dr. Kenneth Cooke is funded in part by The Meredith A. Cowden Foundation.

¹⁴ Dr. Kolja Eppert, a Stephen Birnbaum Scholar, is fully funded by The Stephen Birnbaum Foundation.

¹⁵ Dr. Adolfo Ferrando is funded in part by Eli Lilly and Company and the Rally Foundation for Childhood Cancer Research.

¹⁶ Dr. Jonathan Friedberg is fully funded by Millennium: The Takeda Oncology Company.

¹⁷ Dr. Tarun Kapoor is funded in part by The Robert H. Lyon Leukemia Foundation.

¹⁸ Dr. Karen Keeshan, a Stephen Birnbaum Scholar, is fully funded by The Stephen Birnbaum Foundation.

* Newly awarded or renewed grants in fiscal year 2010

RESEARCH GRANTS CONTINUED

Motonari Kondo, MD, PhD
Duke University Medical Center

Mei Kong, PhD
University of Pennsylvania

Rhett Kovall, PhD*
University of Cincinnati

Valery Krizhanovsky, PhD
Cold Spring Harbor Laboratory

Matthew Krummel, PhD
University of California, San Francisco

Mijung Kwon, PhD*
Dana-Farber Cancer Institute

Samy Lamouille, PhD
University of California, San Francisco

Ke Lan, MD, PhD
University of Pennsylvania

Mark Lanasa, MD, PhD
Duke University Medical Center

Nicolas Larmonier, PhD
University of Arizona

Nicholas Larsen, PhD
Harvard Medical School

Adam Lazorchak, PhD*
Yale University

Sang Eun Lee, PhD
University of Texas
M.D.Anderson Cancer Center

Francene Lemoine, PhD
Northwestern State University of Louisiana

Gustavo Leone, PhD
Ohio State University

Anthony Letai, MD, PhD¹⁹
Dana-Farber Cancer Institute

Anthony Leung, PhD
Massachusetts Institute of Technology

Mark Levis, MD, PhD
Johns Hopkins
University School of Medicine

Erin Lew, PhD*
The Salk Institute for Biological Studies

Zachary Lewis, PhD
University of Oregon

Shaoguang Li, MD, PhD
University of Massachusetts Medical School

Willis Li, PhD
University of Rochester

Zihai Li, MD, PhD
University of Connecticut

Chengyu Liang, MD, PhD
University of Southern California

Sergiy Libert, PhD
Massachusetts Institute of Technology

Weei-Chin Lin, MD, PhD²⁰
University of Alabama at Birmingham

Xin Lin, PhD
University of Texas
M.D.Anderson Cancer Center

Allen Liu, PhD*
The Scripps Research Institute

Ling Liu, PhD
Stanford University

Miao-Chia Lo, PhD
University of California, San Diego

Mignon Loh, MD
University of California, San Francisco

Simonne Longerich, PhD
Yale University

Michelle Longworth, PhD
Massachusetts General Hospital

Li-Fan Lu, PhD
Memorial Sloan-Kettering Cancer Center

Shuo Ma, MD, PhD*
Northwestern University
School of Medicine

Xiaoju Ma, PhD
Harvard Medical School

Yunmei Ma, PhD
Johns Hopkins
University School of Medicine

Hiten Madhani, MD, PhD
University of California, San Francisco

Sebastien Malinge, PhD*
Northwestern University
School of Medicine

Aron Marquitz, PhD
University of North Carolina at Chapel Hill

Daniel Marston, PhD*
University of North Carolina at Chapel Hill

Peter Martin, MD*
Weill Medical College of Cornell University

William Matsui, MD*
Johns Hopkins
University School of Medicine

Alexander Mazin, PhD
Drexel University Medical Center

Ari Melnick, MD²¹
Weill Medical College of Cornell University

Joshua Mendell, MD, PhD
Johns Hopkins
University School of Medicine

Nam-Sung Moon, PhD
McGill University

Tammy Morrish, PhD
Johns Hopkins
University School of Medicine

George Mosialos, PhD
Biomedical Sciences Research Center

Andrew Mungall, PhD*
BC Cancer Agency/
British Columbia Cancer Agency

Anita Nag, PhD
Yale University

Shima Nakanishi, PhD*
Stowers Institute for Medical Research

Geeta Narlikar, PhD²²
University of California, San Francisco

Jeffrey Nolz, PhD*
The University of Iowa

Leta Nutt, PhD
St. Jude Children's Research Hospital

Christopher Oakes, PhD
Deutsches Krebsforschungszentrum
(German Cancer Research Center)

Philipp Oberdoerffer, PhD*
Harvard Medical School

Robert Orłowski, MD, PhD²³
University of Texas
M.D.Anderson Cancer Center

Duoja Pan, PhD
Johns Hopkins
University School of Medicine

Jing Pan, PhD
Memorial Sloan-Kettering Cancer Center

Qishen Pang, PhD
Cincinnati Children's Hospital
Medical Center

Dongsu Park, PhD
Massachusetts General Hospital

Tanya Paull, PhD
The University of Texas at Austin

Alexander Perl, MD²⁴
University of Pennsylvania

Danilo Perrotti, MD, PhD²⁵
Ohio State University

John Perry, PhD
Stowers Institute for Medical Research

Hyewon Phee, PhD
University of California, San Francisco

Christos Polytarchou, PhD
New England Medical Center Hospitals, Inc.

Martin Prlc, PhD
University of Washington

Philippe Prochasson, PhD
University of Kansas Medical Center

Thomas Pucadyil, PhD
The Scripps Research Institute

Miles Pufall, PhD
University of California, San Francisco

Youcun Qian, PhD
Chinese Academy of Sciences

Marc Raaijmakers, MD, PhD*
Massachusetts General Hospital

Ishwar Radhakrishnan, PhD
Northwestern University
School of Medicine

Gunnar Ragnarsson, MD
Fred Hutchinson Cancer Research Center

Noopur Raje, MD*
Massachusetts General Hospital

Rajesh Ramachandran, PhD
The Scripps Research Institute

Dale Ramsden, PhD
University of North Carolina at Chapel Hill

John Randell, PhD
Massachusetts Institute of Technology

Anand Ranjan, PhD
National Cancer Institute

Jeffrey Rathmell, PhD*
Duke University Medical Center

Attila Remenyi, PhD
Eotvos Lorand University

¹⁹Dr. Anthony Letai is fully funded by Millennium: The Takeda Oncology Company.

²⁰Dr. Weei-Chin Lin is funded in part by the Susan Mott Webb Trust and Walter and Beth Grant.

²¹Dr. Ari Melnick is funded in part by Quest Diagnostics, Inc.

²²Dr. Geeta Narlikar is funded in part by Walter and Beth Grant.

²³Dr. Robert Orłowski is funded in part by The Mansbach Foundation.

²⁴Dr. Alexander Perl is funded in part by the Douglas Krill Research Foundation.

²⁵Dr. Danilo Perrotti is funded in part by Mark and Christine Kraemer and Charles and Lynda Kraemer.

Linda Resar, MD²⁶
Johns Hopkins
University School of Medicine

Andrey Revyakin, PhD
University of California at Berkeley

Tannishtha Reya, PhD
Duke University Medical Center

Lauren Richie-Ehrlich, PhD
Stanford University

Robin Ricke, PhD
Mayo Clinic and Foundation

David Rizzieri, MD
Duke University Medical Center

Davide Robbiani, MD, PhD
Rockefeller University

Edward Rogers, PhD
University of North Carolina at Chapel Hill

Theodora Ross, MD, PhD
University of Michigan

Monideepa Roy, PhD
Brigham & Women's Hospital

James Rubenstein, MD, PhD*
University of California, San Francisco

Loredana Ruggeri, MD, PhD
Università di Perugia

Laurent Sabbagh, PhD
University of Toronto

Karen Sachs, PhD
Stanford University

Julien Sage, PhD*
Stanford University

Aaron Schimmer, MD, PhD
University Health Network

Stephen Schoenberger, PhD
La Jolla Institute for Allergy and Immunology

Suzanne Schubert, PhD
University of California, Los Angeles

Ralph Scully, MD, PhD
Beth Israel Deaconess Medical Center

Rosalie Sears, PhD
Oregon Health & Science University

Camile Semighini, PhD
Duke University Medical Center

Neil Shah, MD, PhD*
University of California, San Francisco

Smita Shankar, PhD*
University of California, San Francisco

Sonia Sharma, PhD
Immune Disease Institute

David Sharp, PhD
Albert Einstein College of Medicine

Wei-Jong Shia, PhD²⁷
University of California, San Diego

Warren Shlomchik, MD²⁸
Yale University

Erika Shor, PhD²⁹
University of Wisconsin at Madison

Peter Sicinski, MD, PhD
Dana-Farber Cancer Institute

Rachael Siegel, PhD
Columbia University

Zhou Songyang, PhD
Baylor College of Medicine

Tracy Staton, PhD
Harvard University School of Public Health

Milan Stojanovic, PhD
Columbia University

Travis Stracker, PhD
Institute for Research in Biomedicine

Matthew Strout, MD, PhD
Yale University

Wojciech Swat, PhD
Washington University in St. Louis

Gergely Szakacs, MD, PhD
Institute of Enzymology

Giovanni Tonon, MD, PhD
Fondazione Centro S. Raffaele
del Monte Tabor

Ivan Topisirovic, MD, PhD
McGill University

Emily Troemel, PhD
Massachusetts General Hospital

Jennifer Trowbridge, PhD³⁰
Dana-Farber Cancer Institute

Hsin-yue Tsai, PhD
University of Massachusetts Medical School

Vasiliki Tsakraklides, PhD
Massachusetts Institute of Technology

Katharine Ullman, PhD
University of Utah

Craig Vander Kooi, PhD
University of Kentucky

Lidia Vasilieva, PhD
Oxford University

Shobha Vasudevan, PhD
Massachusetts General Hospital

Suzanne Vercauteren, MD, PhD*
University of British Columbia

Ramiro Verdun, PhD
University of Miami

Jose Villadangos, PhD
Walter & Eliza Hall Institute
of Medical Research

Dan Vogl, MD
University of Pennsylvania

Carl Walkley, PhD
St. Vincent's Institute of Medical Research

Johannes Walter, PhD
Harvard Medical School

Roland Walter, MD, PhD
Fred Hutchinson Cancer Research Center

Demin Wang, PhD³¹
Blood Research Institute

Donghai Wang, PhD
Immune Disease Institute

Gang (Greg) Wang, PhD
Rockefeller University

Mitchell Weiss, MD, PhD
Children's Hospital of Philadelphia

John Welch, MD, PhD*
Washington University in St. Louis

Gerlinde Wernig, MD
Brigham & Women's Hospital

William Wierda, MD, PhD
University of Texas
M.D. Anderson Cancer Center

Sarah Wignall, PhD
Stanford University

Petter Woll, PhD*
University of Oxford

Ning Wu, PhD
Beth Israel Deaconess Medical Center

Tao Wu, PhD
Harvard Medical School

Huafeng Xie, PhD
Dana-Farber Cancer Institute

Ming Xu, PhD³²
Southwestern Medical Center at Dallas

Jianchang Yang, MD, PhD
Nevada Cancer Institute

Xiaolu Yang, PhD
University of Pennsylvania

Tingting Yao, PhD
Colorado State University

Defne Yazar, PhD
Whitehead Institute
for Biomedical Research

Taofei Yin, PhD
University of North Carolina at Chapel Hill

Tong Yin, MD, PhD
Stowers Institute for Medical Research

Carol Ying, PhD
Columbia University

Hoi-Ying (Elsie) Yu, PhD
Brandeis University

Shan Zha, MD, PhD
Children's Hospital Boston

Baochun Zhang, MD, PhD
Immune Disease Institute

Tong Zhang, PhD
Trustees of Dartmouth College

Weiguo Zhang, PhD
Duke University Medical Center

Yanping Zhang, PhD
University of North Carolina at Chapel Hill

Yu Zhang, PhD*
Memorial Sloan-Kettering Cancer Center

Zhengjian Zhang, PhD
University of California, Berkeley

Zhiguo Zhang, PhD*
Mayo Clinic and Foundation

Pengbo Zhou, PhD
Weill Medical College of Cornell University

Rui Zhou, PhD
Harvard Medical School

Yubin Zhou, PhD
Immune Disease Institute

²⁶ Dr. Linda Resar is funded in part by the Cora and John H. Davis Foundation.

²⁷ Dr. Wei-Jong Shia, a Stephen Birnbaum Scholar, is fully funded by The Stephen Birnbaum Foundation.

²⁸ Dr. Warren Shlomchik is fully funded by The Newman Family.

²⁹ Dr. Erika Shor is funded in part by the Greater Milwaukee Foundation's Elsa Schoeneich Medical Research Fund.

³⁰ Dr. Jennifer Trowbridge is funded in part by Tim Banazek, in honor of Taylor St. Pierre and the John W. Alden Trust.

³¹ Dr. Demin Wang is funded in part by Northwestern Mutual Life Foundation, Inc.

³² Dr. Ming Xu is fully funded by the Dallas Saint Valentine's Luncheon and Fashion Show.

* Newly awarded or renewed grants in fiscal year 2010

RESEARCH GRANTS CONTINUED

TRANSLATIONAL RESEARCH PROGRAM

THE TRANSLATIONAL RESEARCH PROGRAM SUPPORTS OUTSTANDING INVESTIGATIONS DEEMED BY OUR EXPERT ADVISORS MOST LIKELY TO TRANSLATE BASIC BIOMEDICAL DISCOVERIES INTO NEW, SAFE AND EFFECTIVE TREATMENTS, ULTIMATELY PROLONGING AND ENHANCING PATIENTS' LIVES.

Albert Baldwin, PhD

University of North Carolina at Chapel Hill

Julio Barredo, MD

University of Miami School of Medicine

Pamela Becker, MD, PhD

University of Washington

Linda Bendall, PhD

University of Sydney

Smita Bhatia, MD

City of Hope National Medical Center

Helen Blau, PhD

Stanford University

Bruce Blazar, MD

University of Minnesota, Twin Cities

Katherine Borden, PhD

Universite de Montreal

Carl Borrebaeck, PhD*

Lund University

John Byrd, MD³³

Ohio State University

Nicola Camp, PhD³⁴

University of Utah

Asher Chanan-Khan, MD

Health Research Incorporated, Roswell Park Cancer Institute Division

Preet Chaudhary, MD, PhD

University of Pittsburgh

Wei Chen, MD, PhD*

University of Minnesota, Twin Cities

Selina Chen-Kiang, PhD*

Weill Medical College of Cornell University

Jason Chesney, MD, PhD*³⁵

University of Louisville
Brown Cancer Center

Kent Christopherson, PhD

Rush University Medical Center

Curt I. Civin, MD

University of Maryland School of Medicine

Michael Cleary, MD

Stanford University

Christopher Cogle, MD

University of Florida

Wendy Cozen, DO

University of Southern California

Alan D'Andrea, MD³⁶

Dana-Farber Cancer Institute

George Daley, MD, PhD

Brigham & Women's Hospital

Chi Dang, MD, PhD

Johns Hopkins
University School of Medicine

James DeGregori, PhD

University of Colorado at Denver

Gerald Denis, PhD

Trustees of Boston University

Maurizio Di Liberto, PhD

Weill Medical College of Cornell University

Gianpietro Dotti, MD

Baylor College of Medicine

Ming-Qing Du, MD, PhD

The University of Cambridge

Elizabeth Eklund, MD*

Northwestern University
School of Medicine

Martin Fernandez-Zapico, MD

Mayo Clinic and Foundation

Adolfo Ferrando, MD, PhD

Columbia University

James Ferrara, MD

University of Michigan

Christopher Flowers, MD*

Emory University

Richard Ford, MD, PhD

University of Texas
M.D. Anderson Cancer Center

Arthur Frankel, M.D.

Scott and White Memorial Hospital

Varsha Gandhi, PhD

University of Texas
M.D. Anderson Cancer Center

Guillermo Garcia-Manero, MD

University of Texas
M.D. Anderson Cancer Center

Celine Gelinas, PhD

UMDNJ – Robert Wood Johnson
Medical School

Alan M. Gewirtz, MD

University of Pennsylvania,
School of Medicine

Jolanta Grembecka, PhD

University of Michigan

Steven Gore, MD*

Johns Hopkins
University School of Medicine

Monica Guzman, PhD³⁷

University of Rochester

Lori Hazlehurst, PhD

H. Lee Moffitt Cancer Center
& Research Institute

Laurence Hurley, PhD, DSC

University of Arizona

Craig Jordan, PhD*³⁸

University of Rochester

Scott Kaufmann, MD, PhD

Mayo Clinic and Foundation

Tomas Kirchoff, PhD

Memorial Sloan-Kettering Cancer Center

Susan Knox, MD, PhD³⁹

Stanford University

Donald Kufe, MD

Dana-Farber Cancer Institute

Wen-Hwa Lee, PhD

University of California at Irvine

Hsiou-Chi Liou, PhD

Weill Medical College of Cornell University

Mignon Loh, MD

University of California, San Francisco

Sagar Lonial, MD

Emory University

Lawrence Lum, MD, DSC

Wayne State University

Nadim Mahmud, MD, PhD

University of Illinois – Chicago

Ari Melnick, MD

Weill Medical College of Cornell University

David Miklos, MD, PhD*

Stanford University

Ramzi Mohammad, PhD

Wayne State University

Jeffrey Moldrem, MD

University of Texas
M.D. Anderson Cancer Center

Sherie Morrison, PhD

University of California, Los Angeles

Markus Muschen, MD⁴⁰

Childrens Hospital Los Angeles

Owen O'Connor, MD, PhD

Columbia University

Vivian Oehler, MD

Fred Hutchinson Cancer Research Center

Craig Okada, MD, PhD

Portland Veterans Affairs Medical Center

Robert Orlowski, MD, PhD

University of Texas
M.D. Anderson Cancer Center

Angel Pellicer, MD, PhD

New York University School of Medicine

Leonidas Plataniias, MD, PhD

Northwestern University
School of Medicine

Feyruz Rassool, PhD

University of Maryland, Baltimore

Yosef Refaeli, PhD*⁴¹

National Jewish Medical
Research Center

Susan Rheingold, MD

The Children's Hospital of Philadelphia

Alain Rook, MD

University of Pennsylvania

Joseph Rosenblatt, MD

University of Miami

Janet Rowley, MD

The University of Chicago

Kathleen Sakamoto, MD⁴²

University of California, Los Angeles

Felipe Samaniego, MD*

University of Texas
M.D. Anderson Cancer Center

Barbara Savoldo, MD, PhD

Baylor College of Medicine

Aaron Schimmer, MD, PhD

University Health Network

Motomu Shimaoka, MD, PhD

Immune Disease Institute

³³ Dr. John Byrd is funded in part by Imagine a Cure for Leukemia.

³⁴ Dr. Nicola Camp is funded in part by Nicholas and Danni Ferrara, Leukemia Research Foundation of Delaware.

³⁵ Dr. Jason Chesney is funded in part by The Mansbach Foundation.

³⁶ Dr. Alan D'Andrea is funded in part by The Robert H. Lyon Leukemia Foundation.

³⁷ Dr. Monica Guzman is funded in part by Robert and JoAnna Behl.

³⁸ Dr. Craig Jordan is funded in part by Robert and JoAnna Behl and the Douglas Kroll Research Foundation.

³⁹ Dr. Susan Knox is funded in part by The Valley Foundation.

⁴⁰ Dr. Markus Muschen is funded in part by the California Community Foundation.

⁴¹ Dr. Yosef Refaeli is funded in part by Big Bill's New York Pizza Deli.

⁴² Dr. Kathleen Sakamoto is funded in part by Parents Against Leukemia and Mike Shevlin.

⁴³ Dr. Benjamin Tycko is funded in part by the Douglas Kroll Research Foundation.

⁴⁴ Dr. David Williams is funded in part by The Marge & Charles J. Schott Foundation and The Harriett R. Downey Fund of the Greater Cincinnati Foundation.

RESEARCH PORTFOLIOS

Margaret Shipp, MD

Dana-Farber Cancer Institute

Alexander Stewart, MD 07 & 09

Mayo Clinic and Foundation

Samuel Strober, MD

Stanford University

Benjamin Tycko, MD, PhD⁴³

Columbia University

Amit Verma, MD

Albert Einstein College of Medicine

Shaomeng Wang, PhD

University of Michigan

Mariusz Wasik, MD*

University of Pennsylvania

David Williams, MD^{*44}

Cincinnati Children's Hospital
Medical Center

James Wooldridge, MD

University of Iowa

Catherine Wu, MD

Dana-Farber Cancer Institute

Mingjiang Xu, MD, PhD

Mount Sinai School of Medicine

B. Hilda Ye, PhD

Albert Einstein College of Medicine

Tim Yen, PhD

Fox Chase Cancer Center

Qing Yi, MD, PhD

University of Texas
M.D. Anderson Cancer Center

Andrew Zannettino, PhD

Institute of Medical and Veterinary Science

Muxiang Zhou, MD

Emory University

Patrick Zweidler-McKay, MD, PhD

University of Texas
M.D. Anderson Cancer Center

LLS RESEARCH PORTFOLIOS ARE GROUPS OF RESEARCH PROJECTS ORGANIZED AROUND A SPECIFIC BLOOD CANCER INTEREST. THE LIST BELOW INCLUDES DONORS THAT GENEROUSLY INVESTED IN A SPECIFIC LLS RESEARCH PORTFOLIO DURING THIS FISCAL YEAR.

Acute Lymphocytic Leukemia Research Portfolio¹

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio²

Chronic Lymphocytic Leukemia Research Portfolio³

Chronic Myelogenous Leukemia Research Portfolio⁴

Hodgkin Lymphoma Research Portfolio⁵

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio⁶

Aggressive Non-Hodgkin Lymphoma Research Portfolio⁷

Indolent Non-Hodgkin Lymphoma Research Portfolio⁸

Pediatric Research Portfolio⁹

Therapy Acceleration Program¹⁰

Waldenstrom Macroglobulinemia Initiative¹¹

Waldenstrom Scientific Research Symposium¹²

¹ Acute Lymphocytic Leukemia Research Portfolio is funded in part by the Peter Burg Memorial Research Fund, Deborah Flanagan – Translational Research Program, David and Kim Savage – Megan's Wings, Inc. and Matt and Diane Schiefferly.

² Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by Howell and Madeline Adams – In memory of Madeline Adams, the Peter Burg Memorial Research Fund, Figg Engineering, For Julie Foundation, Inc., Polly Hatcher Memorial Golf Tournament, The Robert H. Lyon Leukemia Foundation, King & Spalding, LLC, Clyde Smith McGregor, The Roma Foundation – In memory of John Jacob Crane, Friends of Jeff Sachs Campaign, Pat and Jeff Sachs, The Shimkin Foundation and Technology Concepts & Design Inc.

³ Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Helen Anbinder, Stephen and Madeline Anbinder, Brian and Lisa Bee – Spin 4 the Cure, Steve Brannon and Manuel and Sandra Ordonez.

⁴ Chronic Myelogenous Leukemia Research Portfolio is funded in part by the Peter Burg Memorial Research Fund, Rick and Debby Cox and Karen Gentile.

⁵ Hodgkin Lymphoma Research Portfolio is funded in part by Ron and Rosie Kilpatrick and Donald Porteous.

⁶ Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by the Carlson Family Foundation.

⁷ Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by the Peter Burg Memorial Research Fund, J.B. Fuqua Foundation, Headstrong Foundation and The Doug Steele Family, Doug Steele Golf Fore Life Tournament.

⁸ Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Gerry Golub, Timothy and Christine Lindenfelser, Lord, Abbett & Co. LLC and Jerry and Lois Rosenblum.

⁹ Pediatric Research Portfolio is funded in part by Brian and Lisa Bee – Spin 4 the Cure, the Peter Burg Memorial Research Fund, Thomas and Agnes Carvel Foundation, The Jeff Gordon Foundation, Sigma Phi Gamma International Service Sorority, Team Friends of Heroes – Honoring Pediatric Heroes and Wipeout Leukemia Forever Foundation, Inc.

¹⁰ Therapy Acceleration Program is funded in part by the John and Michael Neal Foundation for Cancer Research.

¹¹ Waldenstrom Macroglobulinemia Initiative is fully funded by Peter Bing, International Waldenstrom Macroglobulinemia Foundation and the Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation.

¹² Waldenstrom Scientific Research Symposium is fully funded by the Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation.

* Newly awarded or renewed grants in fiscal year 2010

MEDICAL AND SCIENTIFIC ADVISORS

CHAIR

Armand Keating, MD
Princess Margaret Hospital

VICE CHAIR

Margaret Shipp, MD
Dana-Farber Cancer Institute

Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

David Bodine, PhD
National Institutes of Health

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University

Curt I. Civin, MD
University of Maryland School of Medicine

Jorge Cortes, MD
The University of Texas,
M.D. Anderson Cancer Center

Claude Geoff Davis, PhD
Angelica Therapeutics, Inc.

James H. Davis, PhD, JD
Human Genome Sciences, Inc.

Brian Druker, MD
Howard Hughes Medical Institute,
Oregon Health & Science University
Cancer Institute

David Frantze, JD
Stinson, Morrison, Hecker, LLP

Alan M. Gewirtz, MD
University of Pennsylvania,
School of Medicine

D. Gary Gilliland, MD, PhD
Merck & Co., Inc.

James Griffin, MD
Dana-Farber Cancer Institute

Charles F. Inglefield
American Technical Coatings, Inc.

Judith Karp, MD
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center

Michael W. Long, PhD
Velcura Therapeutics, Inc.

W. Stratford May, Jr., MD, PhD
University of Florida, Shands Cancer Center

Beverly S. Mitchell, MD
Stanford University

Warren S. Pear, MD, PhD
The University of Pennsylvania,
Abramson Family Cancer Research Institute

Kanti R. Rai, MD
Long Island Jewish Medical Center

Steven T. Rosen, MD
Northwestern University,
Robert H. Lurie Comprehensive
Cancer Center

Naomi Rosenberg, PhD
Tufts University School of Medicine

Nancy Speck, PhD
University of Pennsylvania,
School of Medicine

Guido Tricot, MD, PhD
University of Utah, School of Medicine

Cheryl L. Willman, MD
University of New Mexico
Cancer Research and Treatment Center

PROFESSIONAL EDUCATION SUBCOMMITTEE

CHAIR

Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University

Brian Druker, MD
Howard Hughes Medical Institute,
Oregon Health & Science University
Cancer Institute

James Griffin, MD
Dana-Farber Cancer Institute

Judith Karp, MD
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center

Michael W. Long, PhD
Velcura Therapeutics, Inc.

Beverly S. Mitchell, MD
Stanford University Cancer Research Center

Margaret Shipp, MD
Dana-Farber Cancer Institute

ENDOWMENT FUNDS

The Bill Beattie Memorial Endowment Fund (Alberta)

Mary & Robert Bronstein Memorial Fund

The Virginia Major Brooks Memorial Endowment Fund

de Villiers Endowment Fund

Thomas M. Ford Memorial Fund

GlaxoSmithKline Foundation and GlaxoSmithKline, Inc. Research Fund

Jim Jacobs Leukemia Research Fund

The Rachel Kudish Fund

Jane Elissa/Charlotte Meyers Endowment Fund

The Rae Endowment Fund (Ontario)

Vrushali Ranadive Fellowship Fund

Reich Endowment Fund

The UFCW (Canada) Endowment Fund

DONORS

THE BELOW LISTING IS MADE UP OF INDIVIDUALS, FOUNDATIONS AND CORPORATIONS THAT GENEROUSLY SUPPORTED LLS'S MISSION DURING THIS FISCAL YEAR.

\$1,000,000 AND ABOVE

Burlington Coat Factory
 Celgene Corporation
 Centers for Disease Control and Prevention*
 The Simon C. Fireman Charitable Foundation*
 Genentech, Inc.
 Millennium: The Takeda Oncology Company
 Novartis Pharmaceuticals, Inc.
 The Orokawa Foundation
 The Joseph C. Sanfilippo Memorial Fund*
 United Food & Commercial Workers International Union (Canada)
 United Food & Commercial Workers Union (UFCW)

\$500,000 – \$999,999

The Beer Store
 Bristol-Myers Squibb Company
 Carter's, Inc.
 Cephalon Oncology
 Citi
 KGO Newstalk AM 810
 Susan Lang Foundation*
 F.M. Kirby Foundation*
 The Newman Family*
 Wayne and Gladys Valley Foundation*
 Anonymous (1)

\$100,000 – \$499,999

AIG
 Air Products
 Allos Therapeutics, Inc.
 American Electric Power
 Austaco, Inc.
 Robert and JoAnna Behl*
 Big Steaks Management LLC
 Peter Bing*
 The Stephen Birnbaum Foundation*
 BMHC
 Peter Burg Memorial Research Fund
 Citrix Systems
 The Coleman Foundation
 Community Health Charities of New England
 Dallas Saint Valentine's Luncheon and Fashion Show
 DialAmerica

The Harriett R. Downey Fund of the Greater Cincinnati Foundation
 Elbit Systems of America, LLC
 Eli Lilly and Company
 Deborah Flanagan*
 Dworken & Bernstein Co. LPA
 GlaxoSmithKline
 The Jeff Gordon Foundation
 The Hearst Foundation
 Hyundai Hope on Wheels
 Imagine a Cure for Leukemia
 Industrial Alliance Insurance and Financial Services Inc.
 International Waldenström's Macroglobulinemia Foundation*
 Jack's Mannequin
 Virginia Sheldon Jerome Foundation
 Pamela B. Katten Memorial Leukemia Research Foundation
 Sydney and Isobel Kemper
 Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation*
 Laborers' International Union of North America
 Rush Limbaugh
 Timothy and Christine Lindenfelder*
 Lord, Abnett & Co. LLC
 The Mansbach Foundation
 Clyde Smith McGregor
 Mercedes-Benz USA, LLC
 Nike
 Nissan
 Novartis Pharma Canada Inc.
 The Olive Garden Italian Restaurant
 P.F. Chang's China Bistro
 Phoenix Partners Group
 PowerBar
 Province of British Columbia
 Quest Diagnostics, Inc.
 Regence BlueCross BlueShield*
 Runner's World
 Jeff and Pat Sachs*
 The Marge & Charles J. Schott Foundation*
 Schwinn
 Seagate Technology
 Siemens
 Stater Bros. Markets
 Joseph S. and Diane H. Steinberg Charitable Trust*
 Michael and Jacqueline Thomas
 Vistar Corporation
 Wachovia
 WCNN AM 680 The Fan
 Anonymous (2)

\$50,000 – \$99,999

Alion Science & Technology
 American Airlines
 AMERICAN SYSTEMS
 Ham Ansley Memorial Research Fund
 Apache Corporation
 AutoTrader.com
 BAE Systems
 BDO Seidman LLP
 Brian and Lisa Bee – Spin 4 the Cure
 Hildegard D. Becher Foundation Inc.
 The John and Frances Beck Family Foundation*
 Beers + Cutler
 Biogen Idec, Inc.
 Booz Allen Hamilton
 Peter Brock*
 California Community Foundation
 CapitalSource
 Carlson Family Foundation*
 Cisco Systems, Inc.
 Community Health Charities of Minnesota
 Cricket Communications
 Dana West Yacht Club
 Cora and John H. Davis Foundation
 Lawrence J. and Florence A. DeGeorge Charitable Trust
 Deutsche Bank
 Eisai, Inc.
 Future Tech Enterprise, Inc.
 General Dynamics Information Technology
 Walter and Beth Grant*
 Hargrove
 Leon W. (Pete) Harman
 Ed Heitz Memorial Research Fund
 Hirayama Investments, LLC
 Betty Ruth and Milton Hollander
 Human Genome Sciences, Inc.
 IEP/MPG
 In memory of Emerson B. Bridges
 Johnson & Johnson
 Karyn Research Fund*
 William Kenny
 Kohl's Department Stores
 Douglas Kroll Research Foundation
 Lighthouse Investment Partners LLC
 Lunardi Foods
 The Robert H. Lyon Leukemia Foundation
 M&T Bank
 The Harry T. Mangurian, Jr. Foundation, Inc.
 The Todd McClintock Research Fund*
 Media/Professionals Insurance
 Metro Richelieu, Inc.
 Mud Worldwide
 Northrop Grumman Mission Systems

Parents Against Leukemia
 PhRMA
 Ping Y. Tai Foundation, Inc.
 Jonathan Plutzik & Lesley Goldwasser Family Foundation
 PricewaterhouseCoopers LLP
 Raley's Employee Giving Campaign
 Remillard Family Foundation*
 Carroll Rogers
 Richard and Nancy Rogers
 Dale and Esther Roulston
 San Diego Yacht Club
 The Victor E. and Caroline E. Schutte Foundation – Trust E
 Sigma Alpha Epsilon Fraternity, University of Georgia
 Elaine Smith
 John W. & Effie E. Speas Memorial Trust
 Target Corporation
 Team Friends of Heroes – Honoring Pediatric Heroes
 Rick and Susan Theder – Cure Kids Cancer Golf
 Paul Touw
 Toyota
 Transamerica Life Canada
 The Valley Foundation
 Waddell & Reed
 WCCO Radio
 Susan Mott Webb Trust*
 Wells Fargo
 Wilson Farms, Inc.
 Wyeth Pharmaceuticals
 Anonymous (1)

\$10,000 – \$49,999

7-Eleven
 Abbott Oncology
 Accenture
 AIG Highstar
 ACS
 Ann Adams
 Howell and Madeline Adams, Jr., In memory of Madeline Adams
 The Adams Family
 ADJ Sheetmetal

*denotes multi-year commitment

Aegis Media North America	Bayer, Inc.	CA Corporate Headquarters	Chris Cook
Aetna	BD Biosciences	Cadence Design Systems	Diane Cook-Tench
Aetna Foundation	Bedford Falls Foundation	Campbell & Company	Coones Memorial 5K Pumpkin Run-Walk
John W. Alden Trust	Beerman Foundation	Canada Life Assurance Company	CoreMedical Group
Allen & Company, Inc.	Bell Family Foundation	Samuel C. Cantor Charitable Trust	Alverin M. Cornell Foundation
Alliance Data	Bell Microproducts	Capitol Federal	Corporate Synergies
Alliance Holdings, Inc.	Robert Bellas	Capitol File Magazine	Melissa Tsaggaris Corso
Allianz Life Insurance Company of North America	Sheila J. Belsky	Capital Source	Costco Wholesale
Alson Foundation	The Belvedere Cove Foundation	Capstone Advisory Group, LLC	Tim and Maura Costello
The Altschul Foundation/Reichman Memorial	Shelley Bergman	Carter BloodCare	The Meredith A. Cowden Foundation
AlwynCosgrove.com, Inc.	The Bill Bernbach Foundation	Don and Linda Carter	Rick and Debby Cox*
American General Life & Accident	Jay Bernstein	Thomas and Agnes Carvel Foundation	Coyle-Varland Insurance Agency, Inc.
American Health Insurance Plans	Bertrand Berry Foundation	Casino Arizona	Crawl For Cancer
America's Charities	Bert Smith & Co.	Celebree Learning Centers	Louise Creason
Amerimade Technology, Inc.	Berwind Corporation	Center For Executive Development	Creative & Productions Resources, Inc.
AmeriPath, Inc.	Bet Against Cancer	Centric Bank	Credit Suisse
Ames Construction	Big Bill's New York Pizza Deli	CGI	The Cromar Foundation
Amgen, Inc.	BIO	CGI Federal	Crowe Horwath
Helen Anbinder	Alexandra Mayes Birnbaum	CH2MHILL	Cub Foods and Procter & Gamble
Stephen and Madeline Anbinder	Black & Decker	Charles Schwab Corporation	Richard Cullen
John Andrews	The Blackie Foundation	David Chase	Cumberland Packing Corporation
Mark Andrews	The Blackstone Charitable Foundation	The Rhoda and David Chase Family Foundation, Inc.	CXTech
Angler Construction	BlueCross BlueShield	Chiaromonte Construction Company	Cypress Semiconductor
Jennifer Anthony	Edward & Susan Blumenfeld Foundation	Chicago Cubs Charities	Robert Dahl
ARAMARK	Boca Java, Inc.	The Children's Mercy Hospital	DaHunt ForThe Cure, LLC
Robert Arnott	Boca Raton Community Hospital	Chill Media, Inc.	Larry Dale
The Arthur Foundation	Boeing Employees Community Fund	Chittenden	Timothy Daly
Assent, LLC	Nadine Bognar	Chrysler-Jeep-Dodge Advisory Association	Danaher Corporation
Association of Indian Physicians of Northern Ohio	The Bohnen Family Foundation	Cintas	Danford Foundation
AstraZeneca	Herman & Emmie Bolden Foundation	Clark Construction Group, LLC	John Dapper
Astros In Action Foundation	Bombardier Learjet	The Clark Foundation	DARCARS
Avalotis Corporation	Boston Foundation	The Classic Catering People	The Darvish Family
Jerry and Kay Baer	Bowen Engineering Corporation	Clear Channel	Kelvin Davis and Rachel Brewster
Baker Botts, LLP	Helen Brach Foundation	Cleary, Gottlieb, Steen & Hamilton	Davis-Moore Auto Group
Tim Banazek	Donald and Marianne Bradley	Cleveland Indians Baseball Company	Donald and Leona Davis
Banco Popular	Braman Motorcars	CN	DC Rental
Bank of America	Steve and Linda Brannon	The Cornelius J. Coakley Family Foundation	M.C. Dean
The Bank of New York Mellon	Brasscraft-Novi	Coca-Cola North America	Erica Dekko
Bank of Tokyo – Mitsubishi, UJ	Aaron Braun and Joan DeHovitz	Alexandra Cohen	Deloitte
Barbour Griffith & Rogers	Brayton Purcell	The Steven A. and Alexandra M. Cohen Foundation	John DeRosa
Barclays Bank Delaware	Breakthrough Management Group International	Columns Resource Group Foundation, Inc.	Robert and Renee DeVinck
Barefoot Wines	Brecher Design Group	Combined Health Agencies	The Devine Family Foundation
Matthew Barger	The Breeden-Adams Foundation	Commerce Bank	The Dietze Construction Group
Mike and Susie Barnett	Colt Brennan	Community Foundation of Greater Atlanta	Michael Dimson
The Barrett Family Foundation	Brewers of Indiana Guild, Inc.	Community Health Charities of Georgia	DLA Piper
Barroway Topaz Kessler Meltzer & Check, LLP	The Broad Foundation	Community Health Charities of Illinois	Dominick's
BASF Corporation	Brocade	Community Health Charities of Iowa	Dominion Mechanical
Bass Pro Shops	Broward Health	Community Health Charities of New York	Downriver Junior Football League
Carlos Batista Foundation	Brown & Gould	Community Health Charities of Virginia	DPR Construction
Bay 101	Eileen Burg	Community Health Charities of Wisconsin	D.R.A. Properties, LC – Dennis Albaugh
	Burns & McDonnell Foundation	Comstock Homebuilding	Driehaus Capital Management, LLC
	Burson-Marsteller	Contemporary Electrical Services, Inc.	Duffy Mechanical Corp.
	Tim Byrnes	Cook Children's Medical Center	Ed and Anna Dunlap
			Dunn Family Foundation

Duquesne Light Corporation	Friends of Ligonier Polo	George & Mary Josephine Hamman Foundation	Jim Koons Automotive Companies
The Dyer Family Foundation	Paul N. Frimmer, Esq.	The Handlery Foundation	Johnson Controls
E. P. Vaughan Beneficiaries, US Bank Private Client Group	FTI Consulting, Inc.	Eliyahu Harari	Violet M. Johnson Family Foundation
Eagle Bank	Fulbright & Jaworski, LLP	William Harding	Dennis M. Jones Family Foundation
East Bay Community Foundation	Fred Funkhouser	Glen Hart	Gene and Jerry Jones
Easterns Automotive Group	Fred O. Funkhouser Charitable Foundation	Harvard Business School (HBS)	Ralph and Sally Jones
Chris and Joan Edelen	Mrs. Dorothy C. Fuqua	Dave Harvey	JPMorgan Chase
Edwards and Company	J.B. Fuqua Foundation	Polly Hatcher Memorial Golf Tournament	Gerald Kafka and Rita Cavanagh
The Gordon T. & Melissa A. Egan Family Foundation	Furniture Fair	Hausfeld, LLP	Sandra Kahan
James L. Eichberg Foundation	G&T Orthopaedics and Sports Medicine	Nancy Havener	Kaiser Foundation
Steven Eisenstadt	Gap, Inc.	HCL AXON	Paul and Christine Kaplan
Osama El-Atari	Leslie Garfield	Headstrong Foundation	Karches Family Foundation
Elliott Bay Marina, Inc.	Gas America Charitable Foundation	Heavin Family Foundation	The Karches Foundation
Emergent Bio	Chris Gautreau	Hefren-Tillotson, Inc.	Aileen Kass
Emerson Fluid Systems	GE Capital	Hekler-Herman Family Charitable Fund	KCE Structural Engineers
Employees Community Fund of Boeing Wichita	GE Foundation	The Helis Foundation	Christopher Kearns
Energy Enterprise Solutions	GEICO	The Hendin Family	John Kellenyi
Entercom Buffalo	General Dynamics	Heritage Bag Company	Ken Gardiner Modelmaker
Enterprise Rent-A-Car	The General Electric Foundation	David Herro	Kent's 5K Run
Enterprise Rent-A-Car Foundation	General Motors	Jaime Hessler	Kenyon & Kenyon
Ernst & Young LLP	Karen Gentile	Highmark BlueCross BlueShield	Jack and Ellen Kessler
John Esposito	Georgia Power Foundation, Inc.	Hitt Contracting, Inc.	Key Banc Capital Markets
Frank M. Ewing Foundation, Inc.	R. M. Gerstacker Foundation	Freddie Hoffman	Ajit Khubani
Executive Women's Golf Association	The Giannoulas Family	Hoffmann-La Roche Ltd.	Anand Khubani
Exelixis, Inc.	Giant Food Stores	Hogan & Hartson LLP	Chuck Khubani
F.A.L.L. Classic	Charles Gibbs, Jr.	Holt Lundsford Commercial Real Estate, Inc.	Diane Kilmer
Kevin Fairbairn	Gibson Foundation	George and Diana Holway	Ron and Rosie Kilpatrick
FarmerMac	Gila River Casinos	Nance J. Homan	King & Spalding, LLC
FB Foundation	Peter Gilbert	Horizon Foundation of New Jersey	Barbara Kingsborough
Suzanne Fedder	Tom and Laura Gilbert	Jim Houlihan	The Henry White Kinnear Foundation
FedEx/Kinko's	Rob and Cori Glaser	House of Forgings	Neil Kishter
Brian Feltzin	Michael Glover	The Howard Family Foundation	Chuck Kiven
Robert Fenton	Sheila Gold Foundation	Howrey, LLP	The Klein Family Foundation, Inc.
Nicholas and Denni Ferrara, Leukemia Research Foundation of Delaware	Stephen A. & Diana L. Goldberg Foundation, Inc.	Hewlett-Packard Company	Edward Kleinschmidt
FFKR Architects	Gerry Golub	HSBC Bank Canada	The Schley & Lang Knight Foundation
Fidelity Charitable Gift Fund	Glen Gurr	HSBC Bank USA	Koons Automotive Companies
Figg Engineering	Google	Mike Hunter's Team	Stanley Korshak
Grace J. Fippinger Foundation	Grainger	Huron Consulting Group	KPMG LLP
Fireworks For Kids Foundation	David Grais	Bruce & Pricilla Hutchins Family Legacy Endowment	Mark and Christine Kraemer and Charles and Lynda Kraemer
Fitzgerald Family Foundation	The Great-West Life Assurance Company	ICAP Services North America, LLC	The Jeannette and H. Peter Kriendler Charitable Trust
Florentine Camenisch Trust	Greater Milwaukee Foundation's Elsa Schoeneich Medical Research Fund	IDI	The Krutz Foundation
Foley & Lardner	Greenberg Traurig, LLP	Independent Health	KST Data Inc.
For Julie Foundation, Inc.	The Greenbrier Companies	Industrial Alliance Pacific Life Insurance Company	Diane S. Lake Family
FoxKiser	Paul & Beryl Greetin Foundation	The Institute for Transfusion Medicine	
John and Mary Franklin Foundation	T. Kirby Greteman	Insulator's International Health Hazard Fund	
Harrison Frazar	Dawson Grimsley	The Insurance Guys	
Frazier & Deeter Foundation	Grounds Maintenance Services, LLC	International Bank of Commerce	
Andrew Fredman	Donald Guthrie*	Island International Industries, Inc.	
Anthony French	H&R Block	The Jim Jacobs Charitable Foundation	
Virginia Friedhofer Charitable Trust	Dr. Thomas Hahm and Kendra Christmas	The Jake & Johnny Club, Inc.	
Friends of Jeff Sachs Campaign	Walt and Gloria Hallbauer	Alan and Cledith Jennings	
	Hamill Family Trust	The JGB Companies	
	Hamlin Pub, LLC		

 *denotes multi-year commitment

DONORS CONTINUED

Lakefront Communications, Inc.	James McPherson	NewQuest Properties	Poag & McEwen
Marie Lamfrom Charitable Foundation	Timothy McQueen	Kenneth and Bonni Newton	Polo Ralph Lauren Foundation
LandRover Dallas	John Mecray	The New York Mets	William and Sandra Pomeroy
Chris Lantman	Med Assets	Nicholas Family Foundation	Donald Porteous
Christen Laspina	MedImmune, Inc.	Guy and Linda Nohra	Greg Potter
Latham & Watkins	Mellanox Technologies	Nortel Government Solutions	Powell Industries
Cliff and Kristen Lee	The Meltzer Group	North Sails	Prairie Meadows
Kelli Leffingwell Bonacci and The Tony Leffingwell Foundation	The Memorial Foundation	Northrup Grumman	The Pray Family Foundation
Legacy Bank	Memorial Healthcare System	Northrop Grumman Information Technology	Precision Wall Tech
Lehman Brothers	Menkes Developments Inc.	Northside Hospital	John and Monika Preston
Lehman Motors	Merck & Co., Inc.	Northwestern Mutual Life Foundation, Inc.	Price Modern, LLC
Jeffrey Leiserowitz	Metromont	Norton Healthcare	Pro-Air
John and Muffin Lemak	Elaine Meyer	Nuclear Electric Insurance Limited	Protiviti
Martin Liberman	Robert R. Meyer Foundation	Nu-Way Floor Fashions	Providence Alaska Medical Center
Ken and Barbara Lieberman	Microlink	Occidental Petroleum	Providence Health & Services
Steven Lieblich	Microsoft	The Offerdinger Family	Pulse EFT Association, LP
LifeSource	Gary E. Milgard Family Foundation	Shelley Davis O'Hanlon Memorial Fund	Don Putnam
Linebarger Goggan Blair & Sampson	Miller & Long Co., Inc.	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	Puyallup Tribe of Indians
List Innovative Solutions	Karen Miller	OHSU Knight Cancer Institute	Quality Food Center, Inc.
LLS Researchers Team	Todd Miller	OKC Blazers	Rabobank International
Lockheed Martin	Edward Miner	Omaha Community Foundation	The Radley Family Foundation
Donna Loren	Suzy Minkoff	The W. O'Neil Foundation	Raffa, PC
The Lotz Family Foundation	Mizuho Corporate Bank	Oracle Corporation	Rally Foundation for Childhood Cancer Research
LSI Corporation	The Mody Foundation	Manuel and Sandra Ordonez	Stuart Ray
Lucidity Consulting Group	Holly Mohrmann	Oxford Development	Raytheon Company
Lundbeck, Inc.	Harry C. Moores Foundation	Jonathan Pace Foundation	RBC
Lukas Lundin	Morgan Franklin	Park Place Motorcars	Peter Read and Wendy Read-Miller
Jane MacElree	Morgan Stanley	Russell J. Parker	Wayne Reber Foundation
Mackenzie Partners, Inc.	Morris Levine Key Food Stores Foundation, Inc.	Parks, Palmer, Turner & Yemenidjian, LLP	The Reddere Foundation
Malosti Family Ltd. Partnership	Robert Morris	Paul, Hastings, Janofsky & Walker, LLP	Regence
The Employees of Maple Lodge Farms	Alan Morrison	Pen Air Credit Union	The Regence Group
Austin Marrs	The Morrison & Foerster Foundation	Penn Treaty Network America	Regions Bank
Marsh Risk & Insurance Services	Mount Gay Rum	Peoples Health	Michael and Susan Reinfeldt
Martin, Harding & Mazzotti	The Murphy Family	Pepco Holdings, Inc.	Margaret Reynolds
Kenneth Massaroni	James Murphy	Pepsi-Cola Company	Steven Rickmeier
Betty Matoff	Mary Muzikar	The Steven M. Perez Foundation	Ride for Life
Maxim Integrated Products	MVM, Inc.	The Thomas J. & Gerd Perkins Foundation	Rio Grande Cancer Foundation
Maxygen	Joseph Naggar	Sheldon Petersen	Riverside Community Health Foundation
Mayo Foundation	The Harvey E. Najim Family Foundation	James Pettus	Riverside Medical Clinic
McArthurGlen UK Ltd.	Names Family Foundation	Pfizer, Inc.	Robert Michael Communications, Inc.
John McCreadie	Larry A. and Leslie M. Nance	PGA Tour Superstore	Ruth Robinson
The June & Cecil McDole Charitable Fund	National Association of Broadcasters	PGT Trucking	Roche Canada
Casey McGlynn	National City, now part of PNC Financial Services	Phi Gamma Delta Fraternity	Rockville Town Square
Sean and Erin McGould	National Cooperative Services Corporation (NCSC)	Philips Medical Systems	Louise Rogers
McGuire Patmore Foundation	National Pharmaceutical Council	Phillips Nizer, LLP	The Robert M. Rogers Foundation
McKee Nelson, LLP	National Rural Utilities Cooperative Finance Corporation	Phoenix Physicians, LLC	Roma Foundation
McKenna, Long & Aldridge	NBC5	Pillsbury Winthrop Shaw	Ronald D. Paul Companies/Eagle Bank
McKinsey & Company, Inc.	John and Michael Neal Foundation for Cancer Research	Planned Systems International	Rope For Hope
John McLaughlin	NEC Unified Solutions, Inc.	Craig Platenberg	The Rosamond Fund
The McManus Group, LLC	The Netter Foundation	Robin Plonsker	Jerry and Lois Rosenblum
Scott McMullin		PMSLIC	Audrey Ross
The McNichols Family Foundation		PNC Bank	Rothstein Rosenfeldt Adler, Attorneys-at-Law
Francis (Chip) and Kathleen McNamara			Irving Rotter

Brian and Kayla Roughton	Phil and Sally Smart	Thompson, Habib & Denison, Inc.	West Marine
Fred and Bernice Rowan	Douglas A. and Phyllis Smith	Edgar A. Thronson Foundation, Inc.	Virginia Westlake
The Royal Bank of Scotland	Smith Productions	TJX Companies, Inc.	The Frederick and Margaret L. Weyerhaeuser Foundation
Royal Marine Insurance Group	Barry and Meredith Snader	Touchstone Energy Cooperatives	Wheeler Family Charitable Foundation
RR Donnelley	Kevin Sneader	Toyota	Virginia Whetstone
RREEF	Sobey's Distribution Centre	Toyota Motor Sales	Charlie and Shelley Whetzel
Paul & Joan Rubschlager Foundation	Nicholas and Suzann Sopkin	Toyota of Bowie	John Whitaker
Ruby's Diner	Southeast Nebraska Hematology & Oncology	Traino's Wine & Spirits	White & Case, LLP
Runners for Life	Southland Industries	Transamerica Retirement Services	White Castle
George Rush	SouthWest Bank	Travelport	David White
George B. Rush Law Corporation	The Spagenberg Family Foundation	Terri Trevillian	The Whitney Foundation
Safeway, Inc.	Mark and Carol Spisak	TRIB Total Media	WiLine Networks
Sailing World Magazine	Sports Worx	Tropicana Casino and Resort	Williams & Connolly, LLP
Sallie Mae, Inc.	Sprint Nextel	Truland Service Corporation	John Eddie Williams
Lorene Salsbery	St. Joseph's Candler	Mr. and Mrs. Robert Tschudy	Fred Wilpon
Sam's Club Foundation	St. Luke's Mountain States Tumor Institute	Tube City IMS	Winston Partners Group, LLC
The San Francisco Foundation	St. Vincent de Paul Foundation, Inc.	Margaret B. Turner	Wipeout Leukemia Forever Foundation, Inc.
SanDisk	Oliver Stangl	Turner Interiors	WIVB-TV
Annunziata Sanguinetti Foundation	The Doug Steele Family, Doug Steele Golf Fore Life Tournament	Turner Special Projects	Richard and Kaye Woltman
Sarah Cannon Cancer Center/TriStar Health System	Dr. Peter and Sandra Stern	Jack A. Turpin	Woodbine Entertainment
Sarver Charitable Trust	Sterne, Kessler, Goldstein & Fox, PLLC	U.S. Bancorp Foundation	The Woodlands Operating Company
David and Kim Savage, Megan's Wings, Inc.	John Stewart	UBS Investment Bank	Woodmen of the World, Rose City Camp #77
Kelly Scanlan	Stinson Morrison Hecke, LLP	United States Steel Corporation	WTOP Radio
John and Jana Scarpa	Richard Strauss	United Way of Metropolitan Atlanta, Inc.	Emily Wyly
Matt and Diane Schiefferly	Strelmark, LLC	United Way of Southeastern Pennsylvania	In honor of Gustavo Yepes, Jr.
Doris Schmidt	Structural & Steel Products, Inc.	University of Pittsburgh Medical Center	YRC Worldwide
Lee and Laurie Schneider	Structure Tone, Inc.	Christina Valenti	Ziolkowski Patent Solutions Group
Schnuck Markets	Bill Stuckey	Van Burkleo Motors, Inc. – In memory of Bill Van Burkleo	ZIOPHARM Oncology, Inc.
Michael and Susan Schuldes	Style with Substance	Venable LLP	In memory of Ted Zuckerman
The Victor E. and Caroline E. Schutte Foundation – 1959	Sun Capital Partners	Verizon	Joseph Zvesper
Schwab Charitable Fund	Sunesis Pharmaceuticals, Inc.	Vion Pharmaceuticals	Anonymous (15)
Edith M. Schweckendieck Trust	SunTrust Bank	Virginia Mason Medical Center	
Scotia Capital	SureTec	Vitol, Inc.	
Scott Health & Safety	Swanson Group Ltd.	Volkswagen Group of America	
Scotts Miracle-Gro Company	Symantec	Wachovia Securities	
Sedano's Supermarkets	The Taft Foundation	Waddell & Reed Kansas City Marathon	
William Sefton	J.T. Tai & Co. Foundation	Gloria Somerville Wagner	
Carl Sewell	Chris Tarbell	Stephanie Walker Fund	
In memory of Dixie Shadow	Sean and Natalie Tarbell	Mrs. Dwane Wallace	
The Shawver Family	Targeting Lymphoma Shoot	Wal-Mart Foundation	
Mike and Christie Sheffield	TBD Foundation	Walton Construction	
Mike Shevlin	TDS Metrocom	Washington Business Journal	
The Shimkin Foundation	Team Todd	Washington Gas	
Scot and Kathi Shuford	TeamFootWorks	Washington Post Media & Cars.com	
Sidley Austin, LLP	Technology Concepts & Design, Inc.	Waste Management	
Siemens Energy & Automation, Inc.	Televerde	The Waterford Foundation	
Siemens Enterprise Communications, Inc.	TELUS Vancouver Community Board	The Watkins Family	
Sigma Phi Gamma International Service Sorority	The Mike & Mary Terry Family Foundation	Watkins, Meegan, Drury & Company, LLC	
Silicon Valley Community Foundation	Texas Instruments, Inc./Raj Gupta Memorial Fund	Watson Wyatt Worldwide	
Simmonds Family Foundation	Texas Oncology, PA	Anna Webb	
The Sidney, Milton & Leoma Simon Foundation	The M Group/TBD	Wechsler & Marsico Associates	
Robin Singh	Gillis and Billie Thomas	Martin Weinberg	
		Wendy's of Michigan	

 * denotes multi-year commitment

DONORS CONTINUED

TOP CAMPAIGN FUNDRAISERS

INDIVIDUALS WHO HAVE RAISED MORE THAN \$50,000 OR COMPANY TEAMS THAT HAVE RAISED MORE THAN \$100,000 TO SUPPORT LLS'S MISSION.

Tim Banazek	Christy Coyle Moore
BBVA Compass Bank	Scott Murray
Beggin '4 A Cure	Nadine Namoff
Rodney Beverly	Amanda Newsom
Blackstone TNT Team	Tara Pachmayer
Susan Blumenfeld	Anthony Pasko
The Blumenfeld Family	Patti's Team
BMHC	Hap Peden
Burlington Coat Factory	Sarah Jon Porreca
Janet Cervantes	Dan Portillo
Ian Charles	Quest Diagnostics, Inc.
Bruce Cleland	The Riders of the Storm
Citi	MaryJo Robinson & Team Fighting 4 A Cure
Citrix Systems	Dr. David Roer
Detria Courtalis	Carroll Rogers
Emily Currin	Dale and Esther Roulston
Elbit Systems of America, LLC	Lindsey Scott
GE Bright Lights Team	Seagate Technology
Eli Lilly and Company	Joe M. Sergi
Michael C. Fina	Bill Shen
Michelle Fried	Bill Smith
Patricia Giannoulas	Stater Bros. Markets
Dani Greene	Roxanne Tata
Dawson Grimsley†	Team W.O.W.
Habatat for Healing	TUAC
Holt Lunsford Commercial	Vistar
Industrial Alliance	Wachovia
Jack's Mannequin	Tom Wensinger
Ari Jones†	Travis Wilhite and Honore Woodside
Jennifer Keating	Nancy Wilson
William Kenny	Eliana Wolpe
Kiven, Kotler, Lieberman, Fox, Joffe, Goldschmidt, & Kepes Team	Eric Yutzy
Lisa B. Kline	Anonymous (1)
Schley Knight	
Rob LaRocque	
Kathryn Lyon	
Gina Manos	
Jean Mash	
Sarah Milligan	

† National Man & Woman of the Year

THE LEGACY CIRCLE

LEGACY CIRCLE HONORS THOSE WHO NAME LLS IN THEIR WILLS, OR AS BENEFICIARIES OF A TRUST, RETIREMENT ACCOUNT OR INSURANCE POLICY OR ENTER INTO A CHARITABLE GIFT ANNUITY. WE LIST OUR NEWEST MEMBERS BELOW ALONG WITH THOSE WHOSE BEQUESTS OF \$10,000 OR MORE WERE RECEIVED THIS YEAR.

Norman Abel*	Melvin Lintz*
Colean Bailey	Yvonne Lucassen*
Leahbelle Balbach*	Irene Matto*
Louise Barrows*	Lois Mayer*
Doris Bayes*	Lamar McCarty*
Steven and Nancy Bender	Stewart and Vera McDonald*
Stevan and Lynn Berardo	Katie McPadden*
Andrew and Edith Berto*	Ina Meyers*
Edward Blakey*	Chuck and Glenda Michael
Ronald Bogus*	Robert Cleo Mitchell*
Keith Brantley	Peter Moonan*
William and Kathleen Burawski	Barbara Morse*
Mary Lou Bustardo*	Reva Newman*
Coy and Lucille Byerly*	Matthew and Henrietta Norris*
Josip Cajic	Mildred O'Hearn*
Yvonne Cartier*	Stephen O'Keefe
Lois Cartwright	Mary and Andrew Passafaro*
Louise Chamberlain*	Susan Pax*
Lucille Coffey*	Richard and Sarah Pietrafesa
Lauren Cohen*	John Procopio*
Kathleen Culhane*	Rade Ratkovic*
Beatrice Cuneo*	Delana Rauterkus
Steven Decker	Judy Redpath
Grace De Rosso	Dorothy Rittler*
Melvin Dickhaut*	Floyd Rogers*
Julian Dodge*	Michael Rolnick*
Calvin and Ruth Donnelly	Maurice Roseman*
Peggy and Margaret Dupaquier*	Frank Sandler
Ella Mae Fenn*	Norbert Sarnow*
Christina Ferraoli*	Leonard Scharffenberger*
Simon and Norma Fireman	William Hill Sewell
Cesar Gajate*	Irene Sidun
John Gallo*	Dolores Sinkovitz
Nick Gonte*	Robert Smutny*
Ruth Granat*	Fred and Jacqueline Spencer*
Eileen Greene*	Michael Starr
Linda Gunther*	Jacqueline Stern
Julia Gurganus*	Albert and Angeline Strauss*
Ann Harrell*	Bruce and Anne Swartz*
Judith Helfant*	Ann Swoboda*
William Hissey*	Lorraine Walz*
Howard Hveem*	Kerry Weinberg*
Beatrice Jackson*	Catherine Jean Wickenden Mooney*
Carol Johnson*	Genevieve Wilson*
John Kaufmann*	Doris Woychik*
Richard Kelbaugh	Barbara Young
Steven Kleinman*	Ruth Zyskowski
William Krueger*	Anonymous (3)
Jonathan Lehto*	

* Deceased

INDEPENDENT AUDITORS' REPORT

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2009, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Society's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society's 2008 consolidated financial statements and, in our report dated October 20, 2008, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2009, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

KPMG LLP

September 15, 2009

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ JUNE 30, 2009
(WITH COMPARATIVE AMOUNTS AT JUNE 30, 2008) (IN THOUSANDS)

	2009	2008
Assets		
Cash and cash equivalents	\$ 28,196	\$ 36,180
Prepaid expenses and other assets	4,314	4,807
Accounts receivable	75	1,360
Legacies and contributions receivable (note 2)	22,752	7,167
Investments (note 3)	161,623	162,978
Fixed assets, less accumulated depreciation and amortization of \$12,544 and \$12,069	4,616	5,148
Total assets	\$ 221,576	\$ 217,640
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 14,682	\$ 20,700
Deferred revenue	15,479	17,174
Grants payable (notes 4 and 5)	85,768	81,670
Total liabilities	115,929	119,544
Net assets (note 9):		
Unrestricted	78,551	83,085
Temporarily restricted	23,596	11,932
Permanently restricted	3,500	3,079
Total net assets	105,647	98,096
Total liabilities and net assets	\$ 221,576	\$ 217,640

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.

CONSOLIDATED STATEMENT OF ACTIVITIES

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ YEAR ENDED JUNE 30, 2009
(WITH SUMMARIZED TOTALS FOR THE YEAR ENDED JUNE 30, 2008) (IN THOUSANDS)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total	
				2009	2008
Revenue					
Campaign contributions	\$ 260,876	\$ 30,526	\$ 119	\$ 291,521	\$ 304,380
Less direct donor benefit costs	(39,077)	—	—	(39,077)	(42,541)
Net campaign contributions	221,799	30,526	119	252,444	261,839
Legacies	9,198	17,261	—	26,459	6,137
Donated services (note 1)	6,829	—	—	6,829	5,740
Net interest and dividend income (note 3)	6,375	83	9	6,467	7,204
Net (decrease) increase in fair value of investments	(7,159)	(161)	5	(7,315)	(4,839)
Grant refunds	2,768	—	—	2,768	966
Redesignation of net assets	(288)	—	288	—	—
Net assets released from restrictions	36,045	(36,045)	—	—	—
Total revenue	275,567	11,664	421	287,652	277,047
Expenses (note 10)					
<i>Program Services:</i>					
Research	69,786	—	—	69,786	76,979
Patient and community service	93,448	—	—	93,448	77,686
Public health education	41,331	—	—	41,331	42,094
Professional education	8,497	—	—	8,497	8,433
Total program services	213,062	—	—	213,062	205,192
<i>Supporting Services:</i>					
Management and general	23,259	—	—	23,259	24,942
Fund raising	43,132	—	—	43,132	46,052
Total supporting services	66,391	—	—	66,391	70,994
Total expenses	279,453	—	—	279,453	276,186
Change in net assets before foreign currency translation adjustment	(3,886)	11,664	421	8,199	861
Foreign currency translation adjustment	(648)	—	—	(648)	37
Change in net assets	(4,534)	11,664	421	7,551	898
Net Assets					
Beginning of year	83,085	11,932	3,079	98,096	97,198
End of year	\$ 78,551	\$ 23,596	\$ 3,500	\$ 105,647	\$ 98,096

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.


CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ YEAR ENDED JUNE 30, 2009
(WITH COMPARATIVE TOTALS FOR THE YEAR ENDED JUNE 30, 2008) (IN THOUSANDS)

	Program Services					Supporting Services			Total		Direct donor benefit costs	
	Research	Patient and community service	Public health education	Professional education	Total	Management and general	Fund raising	Total	2009	2008	2009	2008
	Awards and grants	\$ 63,542	\$ -	\$ -	\$ -	\$ 63,542	\$ -	\$ -	\$ -	\$ 63,542	\$ 69,134	\$ -
Therapy acceleration program (note 6)	2,294	-	-	-	2,294	-	-	-	2,294	3,941	-	-
Financial aid to patients	-	7,437	-	-	7,437	-	-	-	7,437	6,545	-	-
Co-pay assistance (note 5)	-	19,211	-	-	19,211	-	-	-	19,211	4,560	-	-
Donated services	856	5,973	-	-	6,829	-	-	-	6,829	5,740	-	-
Salaries	1,649	31,118	16,449	4,510	53,726	7,983	9,897	17,880	71,606	70,363	-	-
Employee benefits and taxes (note 7)	222	7,840	4,856	1,299	14,217	2,199	3,376	5,575	19,792	18,020	-	-
Occupancy (note 8)	36	3,546	2,385	658	6,625	1,082	1,465	2,547	9,172	8,727	-	-
Insurance	10	230	162	34	436	66	130	196	632	768	-	-
Telephone	38	2,421	1,075	191	3,725	346	1,140	1,486	5,211	5,715	-	-
Travel	56	883	571	160	1,670	296	339	635	2,305	3,178	13,054	15,183
Printing and supplies	172	2,672	5,641	345	8,830	3,722	9,260	12,982	21,812	24,308	5,781	6,201
Equipment rentals and maintenance	19	841	566	147	1,573	251	397	648	2,221	2,355	-	-
Postage and shipping	71	1,224	3,522	146	4,963	2,020	6,552	8,572	13,535	15,267	-	-
Meetings	485	1,877	814	235	3,411	395	467	862	4,273	6,003	9,127	8,914
Professional fees	304	6,540	4,240	487	11,571	4,171	9,359	13,530	25,101	28,491	3,776	5,280
Miscellaneous	8	996	622	185	1,811	548	404	952	2,763	1,246	7,339	6,963
Depreciation and amortization	24	639	428	100	1,191	180	346	526	1,717	1,825	-	-
Total expenses	\$ 69,786	\$ 93,448	\$ 41,331	\$ 8,497	\$213,062	\$ 23,259	\$ 43,132	\$ 66,391	\$279,453	\$276,186	\$ 39,077	\$ 42,541

EXPENSES

Research	25.0%
Patient and Community Service	33.4%
Public Health Education	14.8%
Professional Education	3.0%
TOTAL PROGRAM SERVICES	76.2%
Management and General	8.3%
Fundraising	15.5%
TOTAL SUPPORTING SERVICES	23.8%
TOTAL EXPENSES	100.0%



SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.

CONSOLIDATED STATEMENT OF CASH FLOWS

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ YEAR ENDED JUNE 30, 2009
(WITH COMPARATIVE AMOUNTS FOR THE YEAR ENDED JUNE 30, 2008) (IN THOUSANDS)

	2009	2008
Cash flows from operating activities:		
Change in net assets	\$ 7,551	\$ 898
Adjustments to reconcile the change in net assets to net cash (used in) provided by operating activities:		
Net decrease in fair value of investments	7,315	4,839
Permanently restricted revenue collected	(119)	(142)
Depreciation and amortization	1,717	1,825
Changes in operating assets and liabilities:		
Accounts receivable	1,285	326
Legacies and contributions receivable	(15,585)	(2,846)
Prepaid expenses	493	(96)
Accounts payable and accrued expenses	(6,018)	1,540
Deferred revenue	(1,695)	1,916
Grants payable	4,098	4,425
Net cash (used in) provided by operating activities	(958)	12,685
Cash flows from investing activities:		
Purchases of fixed assets	(1,185)	(2,317)
Purchases of investments	(186,225)	(200,376)
Sales of investments	180,265	178,276
Net cash used in investing activities	(7,145)	(24,417)
Cash flows from financing activities:		
Permanently restricted contributions collected	119	142
Net cash provided by financing activities	119	142
Net decrease in cash and cash equivalents	(7,984)	(11,590)
Cash and cash equivalents at beginning of year	36,180	47,770
Cash and cash equivalents at end of year	\$ 28,196	\$ 36,180

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ JUNE 30, 2009
(WITH COMPARATIVE AMOUNTS AS OF AND FOR THE YEAR ENDED JUNE 30, 2008)

I. Organization and Significant Accounting Policies

Organization

The Leukemia & Lymphoma Society, Inc. (the "Society") is an international not-for-profit health agency dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin's disease, and myeloma and improving the quality of life of patients and their families. The Society's principal activities include: awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood cancer information made to the Society's Information Resource Center; and disseminating educational information about blood cancers in the form of publications, internet sites, conference calls, and symposia sponsorship for both the medical community and the general public.

Tax-Exempt Status

The Society qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since the Society is publicly-supported, contributions to the Society qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is therefore not subject to income taxes if certain disbursement requirements are met.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Society, which encompasses the Home Office of the Society and its sixty chapters in the United States, LLSC and the Society's not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc. and The Leukemia & Lymphoma Society Research Foundation. All significant inter-company and intra-Society accounts and transactions have been eliminated in consolidation.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Society's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Risks and Uncertainties

The Society invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the statement of financial position.

Summarized Financial Information

The consolidated financial statements are presented with 2008 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2008 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with the Society's 2008 consolidated financial statements from which the summarized information was derived. Certain reclassifications have been made to the 2008 comparative information to conform to the current year presentation.

Subsequent Events

The Society evaluated subsequent events after the statement of position date of June 30, 2009 through September 15, 2009, which was the date the financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to the Society, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of the Society's Board of Directors, for the Society to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period or purpose.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Foreign Currency Transactions and Translation

The consolidated financial statements are prepared in accordance with SFAS No. 52, *Foreign Currency Translation*. The Canadian operation uses the Canadian dollar as the functional currency. Accordingly, the currency impact of the translation of the statement of financial position of the Canadian operation to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements

Effective July 1, 2008, the Society adopted SFAS No. 157, *Fair Value Measurements*. SFAS No. 157 defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy under SFAS No. 157 are as follows:

- Level 1 Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Society has the ability to access at the measurement date
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active
- Level 3 Inputs that are unobservable

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Effective June 30, 2009, the Society elected to apply the concepts of proposed FASB Staff Position (FSP) No. 157-g (FSP 157-g), *Estimating the Fair Value of Investments in Investment Companies That Have Calculated Net Asset Value per Share in Accordance with the AICPA Audit and Accounting Guide, Investment Companies*. As a practical expedient, FSP 157-g permits an investor to estimate the fair value of an investment within the scope of FSP 157-g using the net asset value of the fund without future adjustment.

Contributions and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met.

Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services

The Society has determined that certain of the donated services it receives meet the criteria for recognition in the financial statements. Specifically, the donated services of family support group facilitators and research grant reviewers in the amount of \$6,829,000 have been valued and are reported as both revenue and expense.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ JUNE 30, 2009
(WITH COMPARATIVE AMOUNTS AS OF AND FOR THE YEAR ENDED JUNE 30, 2008)

Cash Equivalents

Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held for long-term purposes reported as investments.

Investments

Investments are stated at fair value based upon quoted market prices, except for the fair values of institutional mutual funds and limited partnerships, which are based on net asset values provided by the fund managers and general partners, respectively, based upon the underlying net assets of the funds consistent with the concepts of proposed FSP 157-g. These values are reviewed and evaluated by management. Investments in limited partnerships are generally less liquid than other investments and the reported fair value may differ from the values that would have been reported had a ready market for these securities existed.

Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, if purchased, or at fair value at date of donation, if contributed, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter.

Recent Accounting Standards

In June 2006, the FASB issued Interpretation No. 48 (FIN 48), *Accounting for Uncertainty in Income Taxes*. In February 2008, the FASB released FSP FIN 48-2, *Effective Date of FASB Interpretation No. 48 for Certain Nonpublic Enterprises*. The Society has determined that it meets the criteria for deferral and has elected to defer the adoption of FIN 48 until after December 15, 2009. Management believes the adoption of FIN 48 will not have a material impact on the Society's consolidated financial statements.

Effective June 30, 2009, the Society adopted the disclosure requirements of FSP FAS 117-1, *Endowments of Not-for-Profit Organizations: Net Asset Classification of Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act, and Enhanced Disclosures for All Endowment Funds* in note 9 of the consolidated financial statements. This FSP also provides guidance on classifying the net assets associated with donor restricted endowment funds held by organizations that are subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act (UPMIFA). New York State has not yet adopted UPMIFA and, accordingly, the Society continues to follow the Uniform Management of Institutional Funds Act (UMIFA).

2. Legacies and Contributions Receivable

The Society's legacies and contributions receivable at June 30, 2009 and 2008 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

	2009	2008
Less than one year	\$ 21,154	\$ 4,886
1 to 5 years	1,630	2,118
After 5 years	163	445
	<u>22,947</u>	<u>7,449</u>
Less discount to present value	(195)	(282)
Total	<u>\$ 22,752</u>	<u>\$ 7,167</u>

At June 30, 2009, approximately 60% of the Society's legacies and contributions receivable was from one estate.

3. Investments

The following is a summary of investments at June 30, 2009 and 2008 (in thousands):

	2009		2008	
	Cost	Fair Value	Cost	Fair Value
Money market funds	\$ 1,514	\$ 1,514	\$ 939	\$ 939
Corporate notes and bonds	62,628	65,884	67,425	67,156
Common stocks and mutual funds	29,411	25,184	33,057	33,301
Government obligations	49,788	50,738	40,532	41,199
Other	25,310	18,303	22,130	20,383
Total	<u>\$ 168,651</u>	<u>\$ 161,623</u>	<u>\$ 164,083</u>	<u>\$ 162,978</u>

Other investments at June 30, 2009 and 2008 consist principally of limited partnerships, the underlying holdings of which are principally marketable securities. Investment expenses of \$568,000 and \$416,000 have been netted against interest and dividend income for the years ended June 30, 2009 and 2008, respectively. The unrealized losses were \$5,923,000 and \$8,869,000 for the years ended June 30, 2009 and 2008, respectively.

All investments at June 30, 2009 are comprised of Level 1 assets except for \$16,303,000 of other investments which are Level 3 assets.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2009 (in thousands).

	Level 3 Assets
Balance at July 1, 2008	\$ 19,334
Purchases	2,000
Investment expense	(103)
Investment income	332
Net decrease in fair value of investments	<u>(5,260)</u>
Balance at June 30, 2009	<u>\$ 16,303</u>

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society's Board of Directors. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society's Board of Directors. In addition to unconditional grants payable of \$85,768,000 at June 30, 2009, the Society has grant commitments of \$74,730,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Co-Pay Assistance Program

The Co-Pay Assistance program offers assistance to patients in meeting their co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Approximately \$7,448,000 is included in the grants payable balance for amounts awarded but unpaid at June 30, 2009.

6. Therapy Acceleration Program ("TAP")

TAP is the Society's strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of the Society's Board of Directors. The Society has contract commitments of \$7,190,000 at June 30, 2009 that are conditioned upon future events and, accordingly, are not recorded.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. ■ JUNE 30, 2009
(WITH COMPARATIVE AMOUNTS AS OF AND FOR THE YEAR ENDED JUNE 30, 2008)

7. Pension Plan

The Society has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expense under this plan aggregated \$4,105,000 and \$3,780,000 for the years ended June 30, 2009 and 2008, respectively.

The Society has a 457(b) Deferred Compensation Plan (the "457 Plan"), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plan approximated \$170,000 and \$134,000 for the years ended June 30, 2009 and 2008, respectively. The assets and liabilities of the 457 Plan are included in investments and accounts payable in the accompanying consolidated statement of financial position and amounted to approximately \$437,000 and \$314,000 at June 30, 2009 and 2008, respectively.

8. Lease Commitments

The leases for premises which the Society's Home Office and chapters occupy expire on various dates through May 31, 2018 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities. The Home Office lease expires in March 2016.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

Year ending June 30:	
2010	\$ 7,243
2011	5,897
2012	4,806
2013	3,100
2014	2,167
Thereafter	<u>3,812</u>
Total	<u>\$ 27,025</u>

9. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2009 and 2008 (in thousands):

	2009		2008	
	Temporarily Restricted	Permanently Restricted	Temporarily Restricted	Permanently Restricted
Time restrictions	\$ 16,566	\$ —	\$ —	\$ —
Research	2,241	2,917	2,913	3,030
Patient service	4,658	420	8,972	—
Other	<u>131</u>	<u>163</u>	<u>47</u>	<u>49</u>
Total	<u>\$ 23,596</u>	<u>\$ 3,500</u>	<u>\$ 11,932</u>	<u>\$ 3,079</u>

The Society has interpreted UMIFA as requiring the preservation of the original gift of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Society classifies permanently restricted net assets at (a) the original value of gifts to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument. The remaining portion of the donor-restricted endowment fund that is not classified as permanently restricted net assets is classified as temporarily restricted net assets to the extent the donor restricted income earned on such endowments to a particular purpose or time, and in all other cases is classified as unrestricted net assets.

The Society has no board-designated endowment funds.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2009 (in thousands).

	Unrestricted	Temporarily restricted	Permanently restricted	Total
Investment income	43	76	9	128
Net (depreciation) appreciation	(710)	(161)	5	(866)
Contributions	—	—	119	119
Net assets released	153	(153)	—	—
Redesignation of net assets	<u>(288)</u>	<u>—</u>	<u>288</u>	<u>—</u>
Endowment net assets at June 30	<u>\$ 1,396</u>	<u>\$ 397</u>	<u>\$ 3,500</u>	<u>\$ 5,293</u>

The Society has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to protect the original value of the gift. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with the Society's overall investment strategy.

10. Joint Costs Allocation

For the years ended June 30, 2009 and 2008, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

	2009	2008
Fund raising	\$ 12,834	\$ 14,505
Patient and community service	1,013	1,161
Public health education	<u>10,188</u>	<u>12,243</u>
Total	<u>\$ 24,035</u>	<u>27,909</u>

NATIONAL LEADERS

CHAIRMAN OF THE BOARD

Steven L. Hooker
The Regence Group
Portland, OR

VICE CHAIR FOR MEDICAL AND SCIENTIFIC AFFAIRS

Armand Keating, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

VICE CHAIR FOR FIELD RELATIONS

Paul J. Cienki
Honeywell
Morristown, NJ

VICE CHAIR FOR PATIENT SERVICES

Marie Lauria, MSW
Chapel Hill, NC

VICE CHAIR FOR RESOURCE DEVELOPMENT

Margaret H. Anderson
Anderson, Bryant, Lasky
& Winslow, PSC
Louisville, KY

SECRETARY/TREASURER

Thomas F. Hunter
Stimulys Performance Marketing
Chesterfield, MO

BOARD OF DIRECTORS

James A. Beck
Hefren-Tillotson, Inc.
Butler, PA

Alexandra Mayes Birnbaum
Peartree Communications, Inc.
New York, NY

Robert A. "Spider" Cantley
Twain Harte, CA

Scott Carroll
Jackson Lewis
Cincinnati, OH

Michael Copley
San Diego, CA

Jorge Cortes, MD
The University of Texas
M.D. Anderson Cancer Center
Houston, TX

Claude Geoffrey Davis
San Mateo, CA

James H. Davis, PhD, JD
Human Genome Sciences, Inc.
Rockville, MD

Timothy Durst
Baker Botts, LLP
Dallas, TX

Thomas L. Fitzpatrick
Saint Gobain Corporation
Worcester, MA

David Frantze, JD
Stinson, Morrison, Hecker, LLP
Kansas City, MO

Paul N. Frimmer
Irell & Manella, LLP
Los Angeles, CA

Alan M. Gewirtz, MD
University of Pennsylvania
School of Medicine
Philadelphia, PA

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Charles F. Inglefield
American Technical Coatings, Inc.
Cleveland, OH

John M. Kamins
Foster, Swift, Collins & Smith, PC
Farmington Hills, MI

Steven Lilly
NRUCFC
Herndon, VA

Michael W. Long, PhD
Velcura Therapeutics, Inc.
Ann Arbor, MI

W. Stratford May, Jr., MD, PhD
University of Florida
Shands Cancer Center
Gainesville, FL

James McKinnis
Rapp Collins Worldwide
El Segundo, CA

Rodman N. Myers
Honigman Miller Schwartz and Cohn
Detroit, MI

Naomi Rosenberg, PhD
Tufts University School of Medicine
Boston, MA

Kevin R. Ryan
Citrin Cooperman & Company, LLP
Philadelphia, PA

Norbert J. Sieber
NJS Consultants
Miami, FL

Jay L. Silver
Baylor College of Medicine, Sugar Land, TX

Mary Simmonds, MD
New Cumberland, PA

Thomas R. Snyder
Nashville Bank and Trust
Nashville, TN

William M. Ward, Jr.
Presbyterian Manors of Mid-America
Wichita, KS

Louise Warner
Chagrin Falls, OH

Kathryn West, RN, MSN, OCN
Amgen
Thousand Oaks, CA

Michele Wong
Synergex International Corporation
Gold River, CA

SENIOR STAFF

PRESIDENT AND CHIEF EXECUTIVE OFFICER

John E. Walter

CHIEF SCIENTIFIC OFFICER RESEARCH & SCIENTIFIC PROGRAMS

Louis DeGennaro, PhD

CHIEF MEDICAL OFFICER RESEARCH & MEDICAL PROGRAMS

Barton Kamen, MD, PhD

CHIEF MARKETING & REVENUE OFFICER

Nancy Klein

CHIEF FINANCIAL OFFICER

Jimmy Nangle

SENIOR VICE PRESIDENT CHIEF INFORMATION OFFICER

Jeff Como

SENIOR VICE PRESIDENT PUBLIC POLICY

George Dahlman

SENIOR VICE PRESIDENT PATIENT SERVICES

Hildy Dillon

SENIOR VICE PRESIDENT FIELD DEVELOPMENT

George Omiros

SENIOR VICE PRESIDENT CHAPTER GROWTH

David Timko

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

CHIEF EXECUTIVE OFFICER

Rudy Putns

GENERAL MANAGER OPERATIONS

Nancy Allen

CHAPTER OFFICES

ALPHABETICAL BY STATE

ALABAMA

ALABAMA/GULF COAST CHAPTER
100 Chase Park South•Suite 220
Birmingham, AL 35244
205.989.0098

ARIZONA

DESERT MOUNTAIN STATES CHAPTER
3877 North 7th Street•Suite 300
Phoenix, AZ 85014
602.567.7600

CALIFORNIA

CENTRAL CALIFORNIA CHAPTER
470 East Herndon•Suite 102
Fresno, CA 93720-2929
559.435.1482

GREATER LOS ANGELES CHAPTER
6033 West Century Boulevard•Suite 300
Los Angeles, CA 90045
310.342.5800

GREATER SACRAMENTO AREA CHAPTER
2143 Hurley Way
Sacramento, CA 95825
916.929.4720

GREATER SAN FRANCISCO BAY AREA CHAPTER
1390 Market Street•Suite 1200
San Francisco, CA 94102-5306
415.625.1100

ORANGE COUNTY INLAND EMPIRE CHAPTER
2020 East First Street•Suite 120
Santa Ana, CA 92705
714.481.5600

SAN DIEGO/HAWAII CHAPTER
9150 Chesapeake Drive•Suite 100
San Diego, CA 92123
858.277.1800

SILICON VALLEY & MONTEREY BAY AREA CHAPTER
675 North First Street•Suite 1100
San Jose, CA 95112-5156
408.490.2666

COLORADO

ROCKY MOUNTAIN CHAPTER
5353 West Dartmouth Avenue•Suite 400
Denver, CO 80227
303.984.2110

CONNECTICUT

CONNECTICUT CHAPTER
372 Danbury Road•Suite 200
Wilton, CT 06897
203.665.1400

DELAWARE

DELAWARE CHAPTER
100 West 10th Street•Suite 209
Wilmington, DE 19801
302.661.7300

FLORIDA

CENTRAL FLORIDA CHAPTER
3319 Maguire Boulevard•Suite 101
Orlando, FL 32803
407.898.0733

NORTHERN FLORIDA CHAPTER
7077 Bonneval Road•Suite 610
Jacksonville, FL 32216
904.332.6414

PALM BEACH AREA CHAPTER
4360 Northlake Boulevard•Suite 109
Palm Beach Gardens, FL 33410
561.775.9954

SOUTHERN FLORIDA CHAPTER
2 Oakwood Boulevard•Suite 200
Hollywood, FL 33020
954.744.5300

SUNCOAST CHAPTER
3507 East Frontage Road•Suite 300
Tampa, FL 33607
813.963.6461

GEORGIA

GEORGIA CHAPTER
3715 Northside Parkway
Building 400•Suite 300
Atlanta, GA 30327
404.720.7900

ILLINOIS

ILLINOIS CHAPTER
651 West Washington Boulevard•Suite 400
Chicago, IL 60661
312.651.7350

INDIANA

INDIANA CHAPTER
941 East 86th Street•Suite 100
Indianapolis, IN 46240
317.726.2270

IOWA

IOWA CHAPTER
8033 University Boulevard•Suite A
Des Moines, IA 50325
515.270.6169 / 800.374.1074

KANSAS

KANSAS CHAPTER
300 North Main•Suite 300
Wichita, KS 67202
316.266.4050

MID-AMERICA CHAPTER
6811 West 63rd Street
Cloverleaf Building #1•Suite 202
Shawnee Mission, KS 66202-4001
913.262.1515

KENTUCKY

KENTUCKY AND SOUTHERN INDIANA CHAPTER
600 East Main Street•Suite 102
Louisville, KY 40202-1077
502.584.8490

MARYLAND

MARYLAND CHAPTER
11350 McCormick Road
Executive Plaza III•Suite 100
Hunt Valley, MD 21031
410.891.1999

MASSACHUSETTS

MASSACHUSETTS CHAPTER
9 Erie Drive•Suite 101
Natick, MA 01760
508.810.1300 / 800.688.6572

MICHIGAN

MICHIGAN CHAPTER
1421 East Twelve Mile Road•Building A
Madison Heights, MI 48071
248.582.2900

MINNESOTA

MINNESOTA CHAPTER
8441 Wayzata Boulevard•Suite 340
Golden Valley, MN 55426
763.852.3000

MISSISSIPPI/LOUISIANA

MISSISSIPPI/LOUISIANA CHAPTER
3636 South I-10 Service Road•Suite 304
Metairie, LA 70001
504.837.0945

MISSOURI

GATEWAY CHAPTER
77 West Port Plaza•Suite 101
Street Louis, MO 63146-3111
314.878.0780

NEBRASKA

NEBRASKA CHAPTER
10832 Old Mill Road•Suite 200
Omaha, NE 68154
402.344.2242

NEVADA

SOUTHERN NEVADA CHAPTER
6280 South Valley View Boulevard•Suite 342
Las Vegas, NV 89118
702.436.4220

NEW JERSEY

NEW JERSEY CHAPTER
14 Commerce Drive•Suite 301
Cranford, NJ 07016
908.956.6608

NEW MEXICO

NEW MEXICO/EL PASO CHAPTER
3411 Candelaria NE•Suite M
Albuquerque, NM 87107
505.872.0141

NEW YORK

LONG ISLAND CHAPTER
555 Broad Hollow Road•Suite 403
Melville, NY 11747
631.752.8500

NEW YORK CITY CHAPTER
475 Park Avenue South•8th Floor
New York, NY 10016
212.376.7100

UPSTATE NEW YORK/VERMONT CHAPTER
5 Computer Drive West•Suite 100
Albany, NY 12205
518.438.3583

WESTCHESTER/HUDSON VALLEY CHAPTER
1311 Mamaroneck Avenue•Suite 130
White Plains, NY 10605
914.949.0084

WESTERN NEW YORK AND FINGER LAKES CHAPTER

4053 Maple Road
Amherst, NY 14226
716.834.2578

NORTH CAROLINA

EASTERN NORTH CAROLINA CHAPTER
401 Harrison Oaks Boulevard•Suite 200
Cary, NC 27513
919.367.4100

WESTERN NORTH CAROLINA CHAPTER
5950 Fairview Road•Suite 250
Charlotte, NC 28210
704.998.5012

OHIO

CENTRAL OHIO CHAPTER
2225 City Gate Drive•Suite E
Columbus, OH 43219
614.476.7194

NORTHERN OHIO CHAPTER
23297 Commerce Park Road
Cleveland, OH 44122
216.910.1200

SOUTHERN OHIO CHAPTER
2300 Wall Street•Suite H
Cincinnati, OH 45212
513.361.2100

OKLAHOMA

OKLAHOMA CHAPTER
500 North Broadway•Suite 250
Oklahoma City, OK 73102
405.943.8888

OREGON/SW WASHINGTON

OREGON/SOUTHWEST WASHINGTON CHAPTER
9320 SW Barbur Boulevard•Suite 140
Portland, OR 97219
503.245.9866

PENNSYLVANIA

CENTRAL PENNSYLVANIA CHAPTER
800 Corporate Circle•Suite 100
Harrisburg, PA 17110
717.652.6520

EASTERN PENNSYLVANIA CHAPTER
555 North Lane•Suite 5010
Conshohocken, PA 19428
610.238.0360

WESTERN PENNSYLVANIA AND WEST VIRGINIA CHAPTER
River Walk Corporate Centre
333 East Carson Street•Suite 441
Pittsburgh, PA 15219
412.395.2873

RHODE ISLAND

RHODE ISLAND CHAPTER
1210 Pontiac Avenue
Cranston, RI 02920
401.943.8888

SOUTH CAROLINA

SOUTH CAROLINA CHAPTER
107 Westpark Boulevard•Suite 150
Columbia, SC 29210
803.731.4060

TENNESSEE

TENNESSEE CHAPTER
404 BNA Drive•Suite 102
Nashville, TN 37217
615.331.2980

TEXAS

CENTRAL TEXAS CHAPTER
9211 Waterford Centre Boulevard•Suite 275
Austin, TX 78758
512.491.6610

NORTH TEXAS CHAPTER
8111 LBJ Freeway•Suite 425
Dallas, TX 75251
972.996.5900

SOUTH TEXAS CHAPTER
950 Isom Road•Suite 125
San Antonio, TX 78216
210.377.1775

TEXAS GULF COAST CHAPTER
5005 Mitchelldale•Suite 115
Houston, TX 77092
713.680.8088

VIRGINIA

VIRGINIA CHAPTER
5511 Staples Mill Road•Suite 202B
Richmond, VA 23228
804.627.0400

WASHINGTON

WASHINGTON/ALASKA CHAPTER
530 Dexter Avenue North•Suite 300
Seattle, WA 98109
206.628.0777

WASHINGTON D.C.

NATIONAL CAPITAL AREA CHAPTER
5845 Richmond Highway•Suite 800
Alexandria, VA 22303
703.399.2900

WISCONSIN

WISCONSIN CHAPTER
200 South Executive Drive
Brookfield, WI 53005
262.790.4701

CANADA

CANADA CORPORATE
804-2 Lansing Square
Toronto, ON M2J 4P8
416.661.9541 x104

BC/YUKON REGION/VANCOUVER CHAPTER

1682 West 7th Avenue•Suite 310
Vancouver, BC V6J 4S6
604.733.2873

ONTARIO REGION/GREATER TORONTO AREA CHAPTER

480 University Avenue•Suite 1502
Toronto, ON M5G 1V2
416.585.2873

PRAIRIES REGION/CALGARY CHAPTER

110-1202 Centre Street S.E.
Calgary, AB T2G 5A5
403.263.5300

QUEBEC REGION/MONTREAL CHAPTER

705-1255 University Street
Montreal, QC H3B 3W1
514.875.1000

WE NEED YOUR HELP
TO KEEP HELPING OTHERS.

60 YEARS OF
INNOVATION

THE LEUKEMIA & LYMPHOMA SOCIETY
IS A NONPROFIT ORGANIZATION
THAT RELIES ON THE GENEROSITY
OF INDIVIDUAL, FOUNDATION
AND CORPORATE CONTRIBUTIONS
TO ADVANCE ITS MISSION.



**The Leukemia &
Lymphoma Society**[®]

Fighting Blood Cancers

1311 MAMARONECK AVENUE ■ SUITE 310 ■ WHITE PLAINS, NY 10605 ■ 914.949.5213 ■ www.lls.org